<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000491.pub3" GROUP_ID="PREG" ID="490299073011290759" MERGED_FROM="" MODIFIED="2015-11-04 13:14:23 +0000" MODIFIED_BY="Leanne Jones" NOTES="&lt;p&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Short title (no longer in use): Treatment duration for bacteriuria in pregnancy&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-11-04 11:19:59 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0157" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2015-11-04 13:14:23 +0000" MODIFIED_BY="Leanne Jones">
<TITLE MODIFIED="2015-10-15 14:45:46 +0100" MODIFIED_BY="Denise Atherton">Duration of treatment for asymptomatic bacteriuria during pregnancy</TITLE>
<CONTACT MODIFIED="2015-11-04 13:14:23 +0000" MODIFIED_BY="Leanne Jones"><PERSON ID="16861" ROLE="AUTHOR"><FIRST_NAME>Mariana</FIRST_NAME><LAST_NAME>Widmer</LAST_NAME><SUFFIX>MSc</SUFFIX><EMAIL_1>widmerm@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>Office X031</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 7912111 ext: 14323</PHONE_1><FAX_1>+41 22 7914171</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-11-04 13:14:23 +0000" MODIFIED_BY="Leanne Jones"><PERSON ID="16861" ROLE="AUTHOR"><FIRST_NAME>Mariana</FIRST_NAME><LAST_NAME>Widmer</LAST_NAME><SUFFIX>MSc</SUFFIX><EMAIL_1>widmerm@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>Office X031</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 7912111 ext: 14323</PHONE_1><FAX_1>+41 22 7914171</FAX_1></ADDRESS></PERSON><PERSON ID="z1412010835492990899900422963295" ROLE="AUTHOR"><FIRST_NAME>Ivana</FIRST_NAME><LAST_NAME>Lopez</LAST_NAME><EMAIL_1>ilopez@crep.org.ar</EMAIL_1><ADDRESS><ORGANISATION>Centro Rosarino de Estudios Perinatales (CREP)</ORGANISATION><CITY>Rosario</CITY><COUNTRY CODE="AR">Argentina</COUNTRY></ADDRESS></PERSON><PERSON ID="15905" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>A Metin</FIRST_NAME><LAST_NAME>Gülmezoglu</LAST_NAME><POSITION>Scientist</POSITION><EMAIL_1>gulmezoglum@who.int</EMAIL_1><URL>http://www.who.int/reproductive-health/rhl/index.html</URL><ADDRESS><DEPARTMENT>UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 7913417</PHONE_1><FAX_1>+41 22 7914171</FAX_1></ADDRESS></PERSON><PERSON ID="AEEB53AF82E26AA200831C190A6F1E33" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Luciano</FIRST_NAME><LAST_NAME>Mignini</LAST_NAME><POSITION>Obstetrician and Gynaecologist/Researcher</POSITION><EMAIL_1>lmignini@crep.org.ar</EMAIL_1><EMAIL_2>lmignini@crep.org.ar</EMAIL_2><ADDRESS><ORGANISATION>Centro Rosarino de Estudios Perinatales (CREP)</ORGANISATION><ADDRESS_1>Pueyrredon 985</ADDRESS_1><CITY>Rosario</CITY><ZIP>2000</ZIP><REGION>Santa Fe</REGION><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>+54 41 483887</PHONE_1><FAX_1>+54 41 483887</FAX_1></ADDRESS></PERSON><PERSON ID="16005" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ariel</FIRST_NAME><LAST_NAME>Roganti</LAST_NAME><EMAIL_1>aroganti@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Servicio de Ginecología</DEPARTMENT><ORGANISATION>Hospital Regional de Ushuaia</ORGANISATION><ADDRESS_1>12 de Octubre y Maipu</ADDRESS_1><ADDRESS_2>Ushuaia</ADDRESS_2><CITY>Tierra del Fuego</CITY><ZIP>CP 9410</ZIP><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>+54 02901423200 ext: 103</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-10-16 09:02:19 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="31" MONTH="8" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="8" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-10-22 09:36:16 +0100" MODIFIED_BY="Heather Maxwell">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-10-22 09:36:16 +0100" MODIFIED_BY="Heather Maxwell">
<DATE DAY="31" MONTH="8" YEAR="2015"/>
<DESCRIPTION>
<P>Search updated and one study added to excluded studies (<LINK REF="STD-Rafalsky-2013" TYPE="STUDY">Rafalsky 2013</LINK>).</P>
<P>Methods updated. 'Risk of bias' tables reassessed. 'Summary of findings' tables (GRADE) added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-10-22 09:35:53 +0100" MODIFIED_BY="Heather Maxwell">
<DATE DAY="31" MONTH="8" YEAR="2015"/>
<DESCRIPTION>
<P>No new included studies added, the conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-09-11 11:34:23 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-09-11 11:34:20 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="8" YEAR="2011"/>
<DESCRIPTION>
<P>Search updated. Three new trials included (<LINK REF="STD-Bayrak-2007" TYPE="STUDY">Bayrak 2007</LINK>; <LINK REF="STD-Estebanez-2009" TYPE="STUDY">Estebanez 2009</LINK>; <LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-09-11 11:34:23 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>The inclusion of a well-designed trial with a large sample size, published in 2009 (<LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK>) contributed significantly to provide a definite answer to this review's question: the one-day antimicrobial treatment is significantly less effective than the seven-day one.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-09-09 11:28:58 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-16 16:15:46 +0100" MODIFIED_BY="Sonja Henderson">
<DATE DAY="31" MONTH="7" YEAR="2006"/>
<DESCRIPTION>
<P>Search updated. We identified one new trial report of an ongoing WHO trial.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-16 16:14:45 +0100" MODIFIED_BY="Sonja Henderson">
<DATE DAY="1" MONTH="5" YEAR="2004"/>
<DESCRIPTION>
<P>We added two new trials to the May 2004 update (<LINK REF="STD-Pregazzi-1987" TYPE="STUDY">Pregazzi 1987</LINK>; <LINK REF="STD-Thoumsin-1990" TYPE="STUDY">Thoumsin 1990</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-10-03 10:30:09 +0100" MODIFIED_BY="Sonja L Henderson">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>HRP-UNDP/UNFPA/WHO/WORLD BANK</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-10-03 10:30:09 +0100" MODIFIED_BY="Sonja L Henderson">
<SOURCE MODIFIED="2015-10-03 10:30:09 +0100" MODIFIED_BY="Sonja L Henderson">
<NAME>UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-11-04 11:19:59 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-11-02 12:21:15 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-02 10:18:08 +0100" MODIFIED_BY="Frances J Kellie">Duration of treatment for asymptomatic bacteriuria during pregnancy</TITLE>
<SUMMARY_BODY MODIFIED="2015-11-02 12:21:15 +0000" MODIFIED_BY="[Empty name]">
<P>Asymptomatic bacteriuria is a urinary tract infection (without symptoms) common in pregnancy. If untreated, it can lead to pyelonephritis (kidney infection). Antibiotic treatment is recommended. This review aimed to identify whether single-dose antibiotic treatments are as effective as longer ones for maternal and newborn outcomes. In general, the risk of bias of trials included in this review was largely unclear. The overall quality of the evidence was assessed using the GRADE approach. The review of 13 studies, involving over 1622 women, found that a seven-day regimen is more effective than a one-day course, especially for the outcome of low birthweight (<I>high quality evidence</I>), but this result is based on just one study. There were no clear differences between a single dose and a four- to seven-day short course of antibiotics for other review outcomes, including kidney infection (<I>very low quality evidence</I>) and preterm birth (<I>moderate quality evidence</I>). Women with a single-dose regimen reported fewer side effects (<I>low quality evidence</I>). More trials are needed to confirm which length of treatment is best for women and babies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-11-02 12:10:45 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-10-24 18:19:56 +0100" MODIFIED_BY="Heather Maxwell">
<P>A previous Cochrane systematic review has shown that antibiotic drug treatment of asymptomatic bacteriuria in pregnant women substantially decreases the risk of pyelonephritis and reduces the risk of preterm delivery. However, it is not clear whether single-dose therapy is as effective as longer conventional antibiotic treatment.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of different durations of treatment for asymptomatic bacteriuria in pregnancy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-10-16 09:03:33 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 August 2015) and reference lists of identified articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized and quasi-randomized trials comparing antimicrobial therapeutic regimens that differed in duration (particularly comparing single dose with longer duration regimens) in pregnant women diagnosed with asymptomatic bacteriuria.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-10-24 18:20:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. We assessed the quality of the evidence using the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-11-02 12:10:45 +0000" MODIFIED_BY="[Empty name]">
<P>We included 13 studies, involving 1622 women. All were comparisons of single-dose treatment with short-course (four- to seven-day) treatments. The risk of bias of trials included in this review was largely unclear, and most trials were at high risk of performance bias. The quality of the evidence was assessed using the GRADE approach. When the any antibiotic agent was used, the 'no cure' rate for asymptomatic bacteriuria in pregnant women was slightly lower for the short-course treatment over the single-dose treatment, although there was evidence of statistical heterogeneity (average risk ratio (RR) 1.28, 95% confidence interval (CI) 0.87 to 1.88; women = 1502, studies = 13; I² = 56%; <I>very low quality evidence</I>). Data from only good quality trials also showed better cure rates with short (four- to seven-day) regimens of the same microbial agent (average RR 1.72, 95% CI 1.27 to 2.33; women = 803, studies = two; I² = 0%; <I>high quality evidence</I>). There was no clear difference in the recurrence of asymptomatic bacteriuria rate between treatment and control groups, whether the same or different microbial agents were used (RR 1.13, 95% CI 0.77 to 1.66; 445 women studies = eight; I² = 0%; <I>very low quality evidence</I>). Differences were detected for low birthweight babies, favoring a short course (four- to seven-day treatment) of the same microbial agent, although the data come from a single trial (RR 1.65, 95% CI 1.06 to 2.57; 714 women; <I>high quality evidence</I>), but no differences were observed for preterm delivery (RR 1.17, 95% CI 0.77 to 1.78; women = 804; studies = three; I² = 23%; <I>moderate quality</I>) or pyelonephritis (RR 3.09, 95% CI 0.54 to 17.55; women = 102; studies = two; I² = 0%; <I>very low quality evidence</I>). Finally, single-dose treatment of any microbial agent was associated with a decrease in reports of 'any side effects' (RR 0.70, 95% CI 0.56 to 0.88; 1460 women, studies = 12; I² = 9%; <I>low quality evidence</I>). Evidence was downgraded for risk of bias concerns in trials contributing data and for imprecise effect estimates (wide confidence intervals crossing the line of no effect, and in some cases, small studies with few events).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-10-24 18:23:38 +0100" MODIFIED_BY="Heather Maxwell">
<P>A single-dose regimen of antibiotics may be less effective than a short-course (four- to seven-day) regimen, but more evidence is needed from large trials measuring important outcomes, such as cure rate. Women with asymptomatic bacteriuria in pregnancy should be treated by the standard regimen of antibiotics until more data become available testing seven-day treatment compared with shorter courses of three- or five-day regimens.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-11-04 11:19:59 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-10-25 09:51:33 +0000" MODIFIED_BY="Heather Maxwell">
<CONDITION MODIFIED="2015-10-24 18:25:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>Asymptomatic bacteriuria, defined as bacterial colonization of the urinary tract without symptomatology, is a common and potentially serious medical complication when it occurs during pregnancy. The incidence of asymptomatic bacteriuria during pregnancy has been reported to be between 2% and 10% (<LINK REF="REF-Andrews-1992" TYPE="REFERENCE">Andrews 1992</LINK>; <LINK REF="REF-Sweet-1977" TYPE="REFERENCE">Sweet 1977</LINK>). <I>Escherichia coli</I> is the most common causative organism followed by organisms such as <I>Staphylococcus saprophyticus</I>, <I>Klebsiella spp</I>, <I>Enterobacter spp</I>, <I>Proteus spp</I>, <I>Enterococcus spp</I>, and others. Between 15% and 45% of pregnant women with asymptomatic bacteriuria, if left untreated, will develop pyelonephritis (<LINK REF="REF-Wang-1989" TYPE="REFERENCE">Wang 1989</LINK>). Pyelonephritis is associated with an increase in maternal and fetal morbidity.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-10-24 18:27:25 +0100" MODIFIED_BY="Heather Maxwell">
<P>There is evidence to show that screening (and treatment) of all pregnant women for asymptomatic bacteriuria is both effective and cost-beneficial when compared to no treatment in reducing the risk of pyelonephritis. A meta-analysis of 11 randomized controlled trials (RCTs) found that treatment of asymptomatic bacteriuria reduced the risk of the development of pyelonephritis when compared to no treatment (<LINK REF="REF-Smaill-2015" TYPE="REFERENCE">Smaill 2015</LINK>). Using decision analysis modeling to compare 'no screening' to 'screening' for asymptomatic bacteriuria, pyelonephritis was shown to decrease from 23.2 cases per 1000 among unscreened pregnant women to 16.20 cases per 1000 in those screened with leukocyte esterase-nitrite dipstick, to 11.2 cases per 1000 among those screened with the more sensitive test of urine culture (<LINK REF="REF-Rouse-1995" TYPE="REFERENCE">Rouse 1995</LINK>). In addition, both dipstick and culture screening were shown to be more cost-beneficial when compared to no screening, and had a high level of agreement in the diagnosis of asymptomatic bacteriuria (<LINK REF="REF-Rouse-1995" TYPE="REFERENCE">Rouse 1995</LINK>).</P>
<P>The association between asymptomatic bacteriuria and preterm delivery has also been studied. Findings from the Cardiff Birth Survey, which prospectively studied 25,844 births, reported that asymptomatic bacteriuria, adjusted for demographic and social factors, was not associated with preterm delivery (odds ratio (OR) 1.20, 95% confidence intervals (CI) 0.90 to 1.50) (<LINK REF="REF-Meis-1995a" TYPE="REFERENCE">Meis 1995a</LINK>). However, when preterm births were categorized into 'indicated' or 'spontaneous' preterm births (<LINK REF="REF-Meis-1995b" TYPE="REFERENCE">Meis 1995b</LINK>), a significant association between bacteriuria and indicated preterm birth was found (OR 2.03, 95% CI 1.50 to 2.80). In an overview of antimicrobial interventions to prevent preterm birth (<LINK REF="REF-Villar-1997" TYPE="REFERENCE">Villar 1997</LINK>), risk of preterm delivery/low birthweight was found to be significantly decreased for pregnant women who had received antibiotic treatment for asymptomatic bacteriuria when compared to women who did not receive treatment (risk ratio (RR) 0.67, 95% CI 0.52 to 0.85). There was an even greater decrease in risk when the only three trials which had categorized preterm delivery separately from low birthweight were considered (RR 0.53, 95% CI 0.33 to 0.86). An earlier meta-analysis of eight RCTs showed that antibiotic treatment significantly reduced the risk of low birthweight (RR 0.56, 95% CI 0.43 to 0.73); however, preterm delivery was not reported independently (<LINK REF="REF-Romero-1989" TYPE="REFERENCE">Romero 1989</LINK>). Another meta-analysis of six RCTs found that antibiotic treatment was associated with a reduction in the incidence of low birthweight babies (RR 0.64, 95% CI 0.45 to 0.93), and also a difference in preterm delivery (<LINK REF="REF-Smaill-2015" TYPE="REFERENCE">Smaill 2015</LINK>). These findings have the limitations that the antibiotic regimens varied, and that many of the antimicrobials may no longer be prescribed in routine clinical practice. Nonetheless, we think that the evidence supports the view that all pregnant women with asymptomatic bacteriuria should be treated to prevent the development of acute pyelonephritis and reduce the risk of preterm delivery.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-10-24 18:29:06 +0100" MODIFIED_BY="Heather Maxwell">
<P>The relatively higher risk of ascending urinary tract infections and pyelonephritis during pregnancy may result from the decrease of ureteral peristalsis due to a progesterone-mediated effect on smooth muscle contractility, on one hand, and the ureteral compression of the gravid uterus on the other. The resulting urinary stasis may facilitate the migration of uropathogens to the upper urinary tract. With eradication of the infection by antibiotic treatment, it is expected to prevent ascending urinary tract infections and the development of clinical pyelonephritis (<LINK REF="REF-Ramsey-2000" TYPE="REFERENCE">Ramsey 2000</LINK>).</P>
<P>The relationship of asymptomatic bacteriuria with low birthweight and preterm delivery is controversial and the possible mechanism involved has not been well established yet. Although both, the microbial colonization of the amniotic fluid and the inflammatory process resulting from the presence of bacteria in neighboring organs may induce uterine contractions, the population of women affected by lower urinary or genital tract infections usually have other risk factors for preterm birth and low birthweight (<LINK REF="REF-Goldenberg-2000" TYPE="REFERENCE">Goldenberg 2000</LINK>) that may act as confounders. However, if the presence of bacteria predispose to premature uterine contractions, the rationale of antibiotic treatment to treat and clear the infection seems reasonable to prevent these adverse neonatal outcomes.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-10-25 09:51:33 +0000" MODIFIED_BY="Heather Maxwell">
<P>The question remains, what is the most effective treatment at the lowest cost, with the fewest side effects? These answers will depend on the pathogen, the choice and duration of antimicrobial, and the available healthcare services. An earlier meta-analysis of seven RCTs reported that a single dose compared to a four- to seven-day antibiotic treatment for bacteriuria showed no statistically significant difference in effectiveness when measuring outcomes of 'cure' and 'recurrence' (<LINK REF="REF-Smaill-1992a" TYPE="REFERENCE">Smaill 1992a</LINK>). However, these studies lacked a uniform definition for 'cure' and 'recurrence', and lacked consistent protocols for follow-up of treatment, making comparisons difficult. Nonetheless, the available data do suggest that single-dose therapy may be as effective as longer, conventional antibiotic treatment. Evidence regarding duration of therapy is especially important because single-dose therapy offers the benefits of greater compliance of women during pregnancy at lower cost. In under-resourced settings, the screening and treatment can be done during the same antenatal care visit.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of the review is to determine the clinical effectiveness of different durations of treatment for asymptomatic bacteriuria in pregnancy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-11-02 12:11:36 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-10-24 18:30:51 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES MODIFIED="2015-10-24 18:30:51 +0100" MODIFIED_BY="Heather Maxwell">
<P>All randomized controlled trials (RCTs) and quasi-RCTs comparing treatment regimens for bacteriuria during pregnancy that differ in duration including those that compared different duration of different antimicrobial agents as well as different durations of the same agent. We expected that the majority of trials would attempt to show equivalence between treatments. We have not included trials comparing different therapeutic agents with the same duration of administration in this review, nor those presented only as abstracts.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women identified during pregnancy as having asymptomatic bacteriuria.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-09-13 18:20:30 +0100" MODIFIED_BY="Frances J Kellie">
<P>Antimicrobials of varying duration. Antimicrobial therapy regimens tend to show large variations in duration. For the purposes of this review, we have considered the following interventions distinct and compared to each other:</P>
<OL>
<LI>single dose (including one-day treatment with divided doses);</LI>
<LI>short course (four to seven days);</LI>
<LI>long course (14 days);</LI>
<LI>continuous (treatment continued until delivery).</LI>
</OL>
<P>We will group interventions that we identify in future that do not fall into one of the categories listed above in the category that is closest in duration. We will make this allocation without any consideration of the trial results.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-06-11 10:48:32 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-04-09 16:08:29 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome is maternal cure rate defined as the woman having negative culture (test of cure) following initial treatment for asymptomatic bacteriuria. </P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-06-11 10:48:32 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">(1) Maternal</HEADING>
<P>(a) Recurrent asymptomatic bacteriuria (in this review, recurrence includes relapse (the recurrence of bacteriuria caused by the same organism, usually within six weeks of the initial infection); and reinfection (the recurrence of bacteriuria involving a different strain of bacteria after successful eradication of the initial infection, limited to the bladder, and occurring at least six weeks after therapy (<LINK REF="REF-Davison-1992" TYPE="REFERENCE">Davison 1992</LINK>)).<BR/>(b) Pyelonephritis.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) Newborn</HEADING>
<P>(a) Preterm delivery (gestational age less than 37 weeks).<BR/>(b) Low birthweight (birthweight less than 2500 g).<BR/>(c) Preterm delivery or low birthweight (if reported together).<BR/>(d) Other birth outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Side effects</HEADING>
<P>Any side effect related to the antibiotic treatment.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-10-16 09:03:47 +0100" MODIFIED_BY="[Empty name]">
<P>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-10-16 09:03:47 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (31 August 2015).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE (Ovid);</LI>
<LI>weekly searches of Embase (Ovid);</LI>
<LI>monthly searches of CINAHL (EBSCO);</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE, Embase and CINAHL, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-02-12 22:39:46 +0000" MODIFIED_BY="Lynn Hampson">
<P>We searched the reference lists of identified articles.</P>
<P>We did not apply any language or date restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-11-02 12:11:36 +0000" MODIFIED_BY="[Empty name]">
<P>For methods used in the previous version of this review, <I>see </I>
<LINK REF="REF-Widmer-2011" TYPE="REFERENCE">Widmer 2011</LINK>.</P>
<P>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group.</P>
<STUDY_SELECTION MODIFIED="2014-09-11 11:41:58 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed for inclusion all the potential studies identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted the third review author.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-09-11 11:49:44 +0100" MODIFIED_BY="[Empty name]">
<P>We designed a form to extract data. For eligible studies, two review authors extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted the third review author. Data were entered into Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) and checked for accuracy.</P>
<P>When information regarding any of the above was unclear, we planned to contact authors of the original reports to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-11-02 12:11:36 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Any disagreement was resolved by discussion or by involving a third assessor.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (e.g. telephone or central randomization; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.1) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low, high or unclear risk of bias for participants;</LI>
<LI>low, high or unclear risk of bias for personnel.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.2) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed methods used to blind outcome assessment as:</P>
<UL>
<LI>low, high or unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</HEADING>
<P>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomized participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we planned to re-include missing data in the analyses which we undertook.</P>
<P>We assessed methods as:</P>
<UL>
<LI>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);</LI>
<LI>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; &#8216;as treated&#8217; analysis done with substantial departure of intervention received from that assigned at randomization);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting (checking for reporting bias)</HEADING>
<P>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</HEADING>
<P>We described for each included study any important concerns we had about other possible sources of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Handbook</I> (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1212181516253162684622876719716&amp;format=REVMAN_GRAPHS#REF-Higgins-2011">Higgins 2011</A>). With reference to (1) to (6) above, we planned to assess the likely magnitude and direction of the bias and whether we considered it is likely to impact on the findings. In future updates, we will explore the impact of the level of bias through undertaking sensitivity analyses - <I>see </I>
<LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of the quality of the evidence using the GRADE approach</HEADING>
<P>For this update, we assessed the quality of the evidence using the GRADE approach as outlined in the <A HREF="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html">GRADE Handbook</A> in order to assess the quality of the body of evidence relating to the following outcomes for the comparisons 'Single-dose antibiotic versus short-course (four- to seven-day) antibiotic', 'Single-dose antibiotic versus long-course (14-day) antibiotic', and 'Single-dose antibiotic versus continuous (treatment continued until delivery) antibiotic'. However, all included trials were of single-dose treatments with short-course (four- to seven-day) treatments and so we were only able to produce 'Summary of findings' tables for this comparison.</P>
<OL>
<LI>No cure</LI>
<LI>Preterm delivery or low birthweight</LI>
<LI>Pyelonephritis</LI>
<LI>Recurrent asymptomatic bacteriuria</LI>
<LI>Any side effect related to the antibiotic treatment</LI>
</OL>
<P>We used <A HREF="http://www.gradepro.org/">GRADEpro</A> Guideline Development Tool to import data from Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) in order to create &#8217;Summary of findings&#8217; tables. A summary of the intervention effect and a measure of quality for each of the above outcomes was produced using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-10-24 18:34:50 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>No continuous data were analyzed. In future updates, if appropriate, we will use the mean difference if outcomes are measured in the same way between trials. We will use the standardized mean difference to combine trials that measure the same outcome, but use different methods.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-10-24 18:35:23 +0100" MODIFIED_BY="Heather Maxwell">
<P>The unit of analysis was individual randomized women.</P>
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomized trials</HEADING>
<P>No cluster-randomized trials were found for this review. If we had identified cluster-randomized trials, they would have been eligible for inclusion.</P>
<P>In future updates, we will include cluster-randomized trials in the analyses along with individually-randomized trials. We will adjust either their sample sizes or standard errors using the methods described in the <I>Handbook</I> <I>[Section 16.3.4 or 16.3.6]</I> using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomized trials and individually-randomized trials, we plan to synthesize the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomization unit is considered to be unlikely.</P>
<P>We will also acknowledge heterogeneity in the randomization unit and perform a sensitivity analysis to investigate the effects of the randomization unit.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>Given the objectives of this review, cross-over trials were not eligible for inclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other unit of analysis issues</HEADING>
<P>No other units of analyses were used in this review.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-10-24 18:35:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>For included studies, we noted levels of attrition. In future updates, if more eligible studies are included, we will explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes, analyses were carried out, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomized to each group in the analyses. The denominator for each outcome in each trial was the number randomized minus any participants whose outcomes were known to be missing. Trials were excluded if it was not possible to enter data on an intention-to-treat basis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-10-24 18:35:51 +0100" MODIFIED_BY="Heather Maxwell">
<P>We assessed statistical heterogeneity in each meta-analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if an I² was greater than 30% and either a Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. Had we identified substantial heterogeneity (above 30%) in the primary outcomes, we planned to explore it by pre-specified subgroup analysis. 
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-09-21 12:27:54 +0100" MODIFIED_BY="Nancy  Medley">
<P>We investigated reporting biases (such as publication bias) using funnel plots. We assessed funnel plot asymmetry visually. If asymmetry was suggested by a visual assessment, we attempted to explain and interpret the finding.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-10-24 18:36:09 +0100" MODIFIED_BY="Heather Maxwell">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials&#8217; populations and methods were judged sufficiently similar.</P>
<P>If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. The random-effects summary was treated as the average range of possible treatment effects and we discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials. If we used random-effects analyses, the results were presented as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I².</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-10-15 14:25:41 +0100" MODIFIED_BY="[Empty name]">
<P>If we identified substantial heterogeneity in the primary outcomes, we investigated it using subgroup analyses and sensitivity analyses. We considered whether an overall summary was meaningful, and if it was, we used random-effects analysis to produce it.</P>
<P>All analyses in the review were set up according to the following clinical subgroups of trials.</P>
<OL>
<LI>Same antimicrobial agent</LI>
<LI>Different antimicrobial agent</LI>
</OL>
<P>Where we had sufficient evidence, we reported a pooled effect estimate. Where there were only data for one of type of antimicrobial, we reported only the evidence we had. We reported positive results of the Test for Subgroup differences where relevant and meaningful. We reported the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-09-21 12:32:51 +0100" MODIFIED_BY="Nancy  Medley">
<P>We planned to carry out sensitivity analyses to explore the effect of trial quality assessed by concealment of allocation, high attrition rates, or both, with poor quality studies being excluded from the analyses in order to assess whether this makes any difference to the overall result. </P>
<P>We carried out the following sensitivity analyses according to trial quality, saved as our Comparison 2.</P>
<OL>
<LI>Good quality studies</LI>
<LI>Poor quality studies</LI>
</OL>
<P>Trial quality was assessed according to whether a trial reported taking measures to prevent selection, detection, performance and attrition bias. Trials reporting these domains were considered of high quality.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-11-02 08:34:55 +0000" MODIFIED_BY="Sonja L Henderson">
<STUDY_DESCRIPTION MODIFIED="2015-10-25 09:43:32 +0000" MODIFIED_BY="Heather Maxwell">
<SEARCH_RESULTS MODIFIED="2015-10-25 09:14:39 +0000" MODIFIED_BY="Heather Maxwell">
<P>We identified two new reports from an updated search in 2015 for the same trial (<LINK REF="STD-Rafalsky-2013" TYPE="STUDY">Rafalsky 2013</LINK>), which we subsequently added to <LINK TAG="EXCLUDED_STUDIES" TYPE="SECTION">Excluded studies</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-10-25 09:43:32 +0000" MODIFIED_BY="Heather Maxwell">
<P>We included 13 studies, involving 1622 women. For a detailed description of studies, <I>see</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>Eleven trials included in the review were conducted in high-income countries (Austria, Belgium, Denmark, Italy, New Zealand, Spain, the United Kingdom, and the United States), and two were conducted in low- and middle-income ones (one multicenter trial conducted in Argentina, Philippines, Thailand, and Viet Nam, and one was conducted in Turkey). The laboratory measurements of selected outcomes required facilities in which urine culture and antibiotic sensitivity testing were possible. Three trials were published recently (<LINK REF="STD-Bayrak-2007" TYPE="STUDY">Bayrak 2007</LINK>; <LINK REF="STD-Estebanez-2009" TYPE="STUDY">Estebanez 2009</LINK>; <LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK>); one of the trials was published in 1990 (<LINK REF="STD-Thoumsin-1990" TYPE="STUDY">Thoumsin 1990</LINK>); eight of the trials were published in the 1980s; and the remaining trial was published in 1975 (<LINK REF="STD-Reeves-1975" TYPE="STUDY">Reeves 1975</LINK>). The antimicrobial drugs used in the trials included: ampicillin, nitrofurantoin, cephalexin, fosfomycin trometamol, fosfomycin, amoxicillin-clavulanate, amoxicillin, co-trimoxazole, trimethoprim, and other sulfonamides. <LINK REF="STD-Bayrak-2007" TYPE="STUDY">Bayrak 2007</LINK> compared a single dose of fosfomycin trometamol with five-day treatment of cefuroxime axetyl; <LINK REF="STD-Thoumsin-1990" TYPE="STUDY">Thoumsin 1990</LINK> compared a single dose of fosfomycin trometamol with seven-day treatment of nitrofurantoin; and <LINK REF="STD-Estebanez-2009" TYPE="STUDY">Estebanez 2009</LINK> compared a single dose of fosfomycin with seven-day treatment of amoxicillin-clavulanate. The remaining 10 trials compared different durations of the same antimicrobial family. The duration of antimicrobial used in the experimental group was either a single dose or one-day treatment with divided dose, and in the control groups, varied between four and seven days' duration. We included <LINK REF="STD-Brumfitt-1982" TYPE="STUDY">Brumfitt 1982</LINK> in spite of inclusion of 24% of symptomatic women in both groups, and <LINK REF="STD-Thoumsin-1990" TYPE="STUDY">Thoumsin 1990</LINK> in spite of the state of publication (preliminary results).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-04-09 16:19:27 +0100" MODIFIED_BY="[Empty name]">
<P>For details of the excluded studies, <I>see</I> table of <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-10-25 09:21:51 +0000" MODIFIED_BY="Heather Maxwell">
<P>In general, the trials lacked evidence of sufficient rigor in the design, conduct and analysis of results (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>For detailed information on methods <I>see </I>table of <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<ALLOCATION MODIFIED="2015-10-25 09:20:01 +0000" MODIFIED_BY="Heather Maxwell">
<P>Generation methods for randomization in six of the 13 trials included computerized process for simple randomization (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Masterton-1985">Masterton 1985</A>), randomized tables (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Brumfitt-1982">Brumfitt 1982;</A> <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Estebanez-2009">Estebanez 2009</A>), and blocked randomization (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Bayrak-2007">Bayrak 2007</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Gerstner-87_x002d_89">Gerstner 87-89</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Lumbiganon-2009">Lumbiganon 2009</A>); all assessed as low risk of bias. Two trials described alternate methods (every other woman) and were assessed as of high risk of bias (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Anderton-1983">Anderton 1983</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Reeves-1975">Reeves 1975</A>). The remaining five trials provided no description of the generation method and were assessed as having an unclear risk of bias (<LINK REF="STD-Bailey-1983" TYPE="STUDY">Bailey 1983</LINK>; <LINK REF="STD-Bailey-1986" TYPE="STUDY">Bailey 1986</LINK>; <LINK REF="STD-Olsen-1989" TYPE="STUDY">Olsen 1989</LINK>; <LINK REF="STD-Pregazzi-1987" TYPE="STUDY">Pregazzi 1987</LINK>; <LINK REF="STD-Thoumsin-1990" TYPE="STUDY">Thoumsin 1990</LINK>).</P>
<P>Seven trials did not describe the mechanism used for allocation concealment (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Brumfitt-1982">Brumfitt 1982</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Estebanez-2009">Estebanez 2009</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Gerstner-87_x002d_89">Gerstner 87-89</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Masterton-1985">Masterton 1985</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Olsen-1989">Olsen 1989</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Pregazzi-1987">Pregazzi 1987</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Thoumsin-1990">Thoumsin 1990</A>) and were assessed as unclear risk of bias. One trial used numbered treatment bags (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Bayrak-2007">Bayrak 2007</A>), another used sealed, opaque treatment boxes numbered sequentially (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Lumbiganon-2009">Lumbiganon 2009</A>) and were considered as low risk of bias; and two described concealment as 'envelopes' only (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Bailey-1983">Bailey 1983</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Bailey-1986">Bailey 1986</A>); these trials were assessed as having an unclear risk of bias. The remaining two trials (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Anderton-1983">Anderton 1983</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Reeves-1975">Reeves 1975</A>) used alternated methods for allocation and were assessed as at high risk of bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-07-01 15:51:53 +0100" MODIFIED_BY="[Empty name]">
<P>In all 13 trials, there was inadequate description to determine whether 'contamination' in the short-course treatment group, co-interventions, or protocol deviation occurred. Blinding for outcome assessment was reported in three trials (<LINK REF="STD-Bayrak-2007" TYPE="STUDY">Bayrak 2007</LINK>; <LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK>; <LINK REF="STD-Masterton-1985" TYPE="STUDY">Masterton 1985</LINK>). No women were blinded to treatment in any of the trials except in the <LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK> trial. Informed consent was mentioned in the majority of trials.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-10-25 09:20:39 +0000" MODIFIED_BY="Heather Maxwell">
<P>Loss to follow-up was described in all trials except <LINK REF="STD-Brumfitt-1982" TYPE="STUDY">Brumfitt 1982</LINK>, <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Pregazzi-1987">Pregazzi 1987</A> and <LINK REF="STD-Thoumsin-1990" TYPE="STUDY">Thoumsin 1990</LINK>; all assessed as of unclear risk of bias. The rates of loss to follow-up were, as expected given the longer duration, generally higher in the comparison group as compared to the experimental (single-dose) group. Although the numbers are small, when two treatments produce a different pattern of withdrawal, then this offers evidence that the groups are not entirely comparable (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#REF-Jones-1996">Jones 1996</A>). Several trials had small differences in rates of loss between treatment arms and were assessed as of low risk of bias (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Anderton-1983">Anderton 1983</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Bailey-1983">Bailey 1983</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Bailey-1986">Bailey 1986</A>; <LINK REF="STD-Bayrak-2007" TYPE="STUDY">Bayrak 2007</LINK>; <LINK REF="STD-Estebanez-2009" TYPE="STUDY">Estebanez 2009</LINK>; <LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK>; <LINK REF="STD-Masterton-1985" TYPE="STUDY">Masterton 1985</LINK>; <LINK REF="STD-Olsen-1989" TYPE="STUDY">Olsen 1989</LINK>; <LINK REF="STD-Reeves-1975" TYPE="STUDY">Reeves 1975</LINK>). <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Gerstner-87_x002d_89">Gerstner 87-89</A>, though, we assessed as of high risk due to 13% loss in the treatment arm and 26% loss in the control arm.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-09-04 10:25:15 +0100" MODIFIED_BY="Nancy  Medley">
<P>The only trial that reported on the demographics or number of women who met the study eligibility criteria, but were not included in the study and also on compliance with the treatment regimen, was <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Lumbiganon-2009">Lumbiganon 2009</A>; this trial was assessed as of low risk of reporting bias. All other trials were assessed as of unclear risk of bias due to lack of information.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-10-25 09:21:51 +0000" MODIFIED_BY="Heather Maxwell">
<P>An explanation of the sample size calculation and power calculation was provided in the <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Bayrak-2007">Bayrak 2007</A>, <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Lumbiganon-2009">Lumbiganon 2009</A> and <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Masterton-1985">Masterton 1985</A> trials; these trials were assessed as of low risk of other sources of bias.</P>
<P>All of the remaining trials were assessed as of unclear risk of bias due to lack of information in the trial report or to specific factors where we were unclear of the impact of potential bias. For example, randomization is less effective in achieving comparable groups in studies with small sample sizes, which many of our studies had. Also, in one trial women in the experimental group were more likely to have a history of urinary tract infection as compared to the control group (50% versus 35%) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#STD-Bailey-1983">Bailey 1983</A>). Disparity in baseline characteristics between treatment groups suggests selection bias due to inadequate randomization or too small a sample size, or both (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241355113458678826008616212&amp;format=REVMAN#REF-Villar-1996">Villar 1996</A>). We felt there was an increased likelihood of selection bias in most of the trials, but we were unclear of the impact of this bias on results. The total number of women enrolled in these studies ranged from 41 to 778.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-11-02 08:34:55 +0000" MODIFIED_BY="Sonja L Henderson">
<SUBSECTION>
<HEADING LEVEL="3">Comparison <I>1: </I>Single-dose antibiotic versus short-course (four- to seven-day) antibiotic for asymptomatic bacteriuria</HEADING>
<P>We included 13 trials, involving 1622 women. After reporting overall results, we report individual results for two groups: (a) trials that compared different duration regimens of the same agent; and (b) trials that compared different duration regimens of different antimicrobial agents.</P>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 1: overall pooled totals for all trials</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<P>
<B>No cure</B>
</P>
<P>Cure rates were similar whether women received a single dose or a short course of any antibiotic (average risk ratio (RR) 1.28, 95% confidence interval (CI) 0.87 to 1.88; women = 1502; studies = 13; I² = 56%; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There was no evidence of differences in cure rates for our subgroups of same antimicrobial agent or different microbial agent (Test for subgroup differences: Chi² = 0.55, (P = 0.46), I² = 0%) and moderate heterogeneity even with a random-effects model (Heterogeneity: Tau² = 0.23; Chi² = 27.00, I² = 56%). We graded the evidence for the outcome of no cure as very low quality due to risk of bias in the contributing trials and wide CIs crossing the line of no effect.</P>
<P>When assessing forest plots for publication bias, we found suggested asymmetry in the funnel plot for this outcome (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). However, the single outlier trial was extremely small, and so the source of asymmetry may well be a small-study effect rather than publication bias. This trial also contribute very little to the overall pooled effect estimate (1.6%). We have not downgraded evidence for this outcome for publication bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Maternal and newborn outcomes</HEADING>
<P>
<B>Recurrent asymptomatic bacteriuria</B>
</P>
<P>Rates of recurrence were similar between treatment groups (RR 1.13, 95% CI 0.77 to 1.66; women = 445; studies = eight; I² = 0%), <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>. There was no evidence of any difference between subgroups of the same or different agents (Test for subgroup differences: Chi² = 0.03, (P = 0.86), I² = 0%). We graded evidence for recurrence as very low due to risk of bias concerns in the contributing trials and wide CIs crossing the line of no effect.</P>
<P>Results for outcomes (pyelonephritis, preterm delivery and low birthweight) <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> were not pooled due to each outcome only having one subgroup. Results for these outcomes are found below for trials with either the same or different agents.</P>
<P>
<B>Side effects </B>
</P>
<P>Fewer women who had the single dose experienced side effects (RR 0.70, 95% CI 0.56 to 0.88; women = 1460; studies = 12; I² = 9%), <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>. Evidence for side effects was graded to be of low quality due to risk of bias concerns in the trials contributing data. There was evidence of a difference between using the same or different microbial agents noted; however, we would not emphasize this finding due to the small number of trials and events in the different antimicrobial group. The results for both subgroups fall in the same direction with minimal heterogeneity (Test for subgroup differences: Chi² = 5.42, df = 1 (P = 0.02), I² = 81.5%; Heterogeneity: Chi² = 10.93, I² = 9%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 1: (a) different duration of the same antimicrobial agent</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<P>
<B>No cure</B>
</P>
<P>All trials reported bacteriological success of treatment by repeat cultures (<LINK REF="STD-Anderton-1983" TYPE="STUDY">Anderton 1983</LINK>; <LINK REF="STD-Bailey-1983" TYPE="STUDY">Bailey 1983</LINK>; <LINK REF="STD-Bailey-1986" TYPE="STUDY">Bailey 1986</LINK>; <LINK REF="STD-Brumfitt-1982" TYPE="STUDY">Brumfitt 1982</LINK>; <LINK REF="STD-Gerstner-87_x002d_89" TYPE="STUDY">Gerstner 87-89</LINK>; <LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK>; <LINK REF="STD-Masterton-1985" TYPE="STUDY">Masterton 1985</LINK>; <LINK REF="STD-Olsen-1989" TYPE="STUDY">Olsen 1989</LINK>; <LINK REF="STD-Pregazzi-1987" TYPE="STUDY">Pregazzi 1987</LINK>; <LINK REF="STD-Reeves-1975" TYPE="STUDY">Reeves 1975</LINK>) The 'no cure' rate was similar for the one-day and the four- to seven-day treatment (average RR 1.34, 95% CI 0.85 to 2.12; women = 1286; studies = 10; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There was moderate heterogeneity for this outcome even with a random-effects model (Heterogeneity: Tau² = 0.30; Chi² = 25.83, df = 9 (P = 0.002); I² = 65%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(a) Maternal outcomes</HEADING>
<P>The risk of <B>recurrent asymptomatic bacteriuria</B> (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) in one-day treatment was not significantly different to that with longer treatment (RR 1.12, 95% CI 0.76 to 1.66; women = 313; studies = six; I² = 0%).</P>
<P>
<B>Pyelonephritis</B> (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) was reported only by <LINK REF="STD-Bailey-1983" TYPE="STUDY">Bailey 1983</LINK> and <LINK REF="STD-Bailey-1986" TYPE="STUDY">Bailey 1986</LINK>, with 102 women included in the two trials together. There were four more women with pyelonephritis following single-dose treatment (5/54 versus 1/48; RR 3.09, 95% CI 0.54 to 17.55; women = 102; studies = two; I² = 0%). We graded evidence for this outcome as of very low quality due to risk of bias concerns in the contributing trials, wide CIs and limited data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(b) Newborn outcomes</HEADING>
<P>
<B>Preterm birth</B>
</P>
<P>Only three of the 10 trials included in this review reported preterm birth rates (<LINK REF="STD-Bailey-1983" TYPE="STUDY">Bailey 1983</LINK>; <LINK REF="STD-Bailey-1986" TYPE="STUDY">Bailey 1986</LINK>; <LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK>). In total, 804 women were studied in these trials (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), and there is no evidence of a difference between a single-dose antibiotic and a four- to seven-day course (RR 1.17, 95% CI 0.77 to 1.78; women = 804; studies = three; I² = 23%). We graded evidence for preterm birth to be of moderate quality due to imprecision, or wide CIs crossing the line of no effect.</P>
<P>
<B>Low birthweight</B>
</P>
<P>Just one trial <LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK> reported low birthweight rates (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) with 48 cases out of 364 babies in the one-day arm compared to 28 cases in the 350 babies from the longer-treatment group (RR 1.65, 95% CI 1.06 to 2.57; women = 714; studies = one; I² = 0%). Evidence for low birthweight was graded as of high quality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(c) Side effects</HEADING>
<P>The meta-analysis regarding any side effects (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) shows a lower incidence of side effects with single-dose treatment. For those trials that tested the same microbial agent the result is similar (RR 0.77, 95% CI 0.61 to 0.97; women = 1244; studies = nine; I² = 0%). The <LINK REF="STD-Reeves-1975" TYPE="STUDY">Reeves 1975</LINK> study included in this analysis was stopped prematurely due to the side effects (mainly nausea, vomiting, diarrhea) of sulfadimidine in seven-day treatment group. A sensitivity analysis including all trials comparing the same antimicrobial but excluding <LINK REF="STD-Reeves-1975" TYPE="STUDY">Reeves 1975</LINK> also showed higher, yet statistically non-significant, rates of similar side effects with longer treatment (RR 0.81, 95% CI 0.64 to 1.04).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 1 (b): different durations of different antimicrobial agents</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<P>
<B>No cure</B>
</P>
<P>The three trials included in this outcome (216 women) reported bacteriological success of treatment by repeat cultures (<LINK REF="STD-Bayrak-2007" TYPE="STUDY">Bayrak 2007</LINK>; <LINK REF="STD-Estebanez-2009" TYPE="STUDY">Estebanez 2009</LINK>; <LINK REF="STD-Thoumsin-1990" TYPE="STUDY">Thoumsin 1990</LINK>). There was no difference in the 'no cure' rate for the single-dose treatment versus the short-course treatment, but with wide CIs (RR 0.98, 95% CI 0.49 to 1.95; women = 216; studies = three; I² = 0%), <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(a) Maternal outcomes</HEADING>
<P>
<B>Recurrent asymptomatic bacteriuria</B>
</P>
<P>The incidence of recurrent bacteriuria was reported in two of the three included trials (<LINK REF="STD-Estebanez-2009" TYPE="STUDY">Estebanez 2009</LINK>; <LINK REF="STD-Thoumsin-1990" TYPE="STUDY">Thoumsin 1990</LINK>) (132 women), and there was no significant difference between the two groups, again with wide CIs (RR 1.32, 95% CI 0.23 to 7.46), <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.</P>
<P>
<B>Pyelonephritis</B>
</P>
<P>No trial included in this subgroup of different agents reported the outcomes of pyelonephritis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(b) Newborn outcomes</HEADING>
<P>No trial included in this subgroup of different agents reported the outcomes of preterm birth or low birthweight.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(c) Side effects</HEADING>
<P>The three trials (<LINK REF="STD-Bayrak-2007" TYPE="STUDY">Bayrak 2007</LINK>; <LINK REF="STD-Estebanez-2009" TYPE="STUDY">Estebanez 2009</LINK>; <LINK REF="STD-Thoumsin-1990" TYPE="STUDY">Thoumsin 1990</LINK>) showed fewer side effects in the single-dose treatment group than in the short-course treatment group (RR 0.16, 95% CI 0.04 to 0.58; women = 216; studies = three; I² = 0%), <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: Single-dose antibiotic versus short-course (four- to seven-day) antibiotic for asymptomatic bacteriuria</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis by trial quality</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 2 (1): same antimicrobial agent - 'no cure'</HEADING>
<P>When grouped by trial quality (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), the two trials of good quality (reporting measures to prevent selection, detection, performance and attrition bias) show a significant increase in 'no cure' rates with single-dose treatment when compared with short-course (four- to seven-day) treatment (<LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK>; <LINK REF="STD-Masterton-1985" TYPE="STUDY">Masterton 1985</LINK>; two trials, 803 women, average RR 1.72, 95% CI 1.27 to 2.33; Heterogeneity: Chi² = 0.35, df = 1 [P = 0.55]; I² = 0%). Heterogeneity remains in the subgroup of poor quality studies (eight trials, 483 women, average RR 1.32, 95% CI 0.73 to 2.42, Heterogeneity: Chi² = 20.84, df = 7 (P = 0.004); I² = 66%). There was some evidence that the intervention worked differently, and better, in trials of higher quality, although the test for subgroup was not significant (Test for subgroup differences: Chi² = 0.58, df = 1 (P = 0.44), I² = 0%). However, there were only two studies in the good quality subgroup and the CIs for both pooled results do overlap.</P>
<P>We have graded the evidence for no cure (good quality studies) as of high quality. See <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 2 (2): different antimicrobial agent - 'no cure'</HEADING>
<P>When grouped by trial quality, only <LINK REF="STD-Bayrak-2007" TYPE="STUDY">Bayrak 2007</LINK> shows relatively good quality. There was no difference in rates of no cure with a single dose or short-course doses (one study, RR1.36, 95% CI 0.24 to 7.75), <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>. The remaining two trials were ranked as of poor quality; these trials also show no group differences in rates of no cure (two studies, RR 0.93, 95% CI 0.44 to 1.96. Heterogeneity: Chi² = 0.22, df = 1 (P = 0.64); I² = 0%). There was no evidence of a difference between subgroups of high or low quality studies (Test for subgroup differences: Chi² = 0.16, df = 1 (P = 0.69), I² = 0%), but there were too few trials in each subgroup to make this analysis meaningful.</P>
<P>We have graded the evidence for no cure (good quality studies) as of low quality, due to the estimate coming from a single small trial and having wide CIs crossing the line of no effect.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3: Single-dose antibiotic versus long-course (14 days) antibiotic for asymptomatic bacteriuria</HEADING>
<P>No trials found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 4: Single-dose antibiotic versus continuous (treatment continued until delivery) antibiotic for asymptomatic bacteriuria</HEADING>
<P>No trials found.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-11-04 11:19:59 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-10-25 09:35:05 +0000" MODIFIED_BY="Heather Maxwell">
<P>Asymptomatic bacteriuria during pregnancy has serious consequences if it is not treated. Routine screening and antibiotic treatment of positive cases is generally recommended. The optimal duration of the treatment has both cost and practical implications.The standard treatment is a short course of four to seven days. Single-dose treatment, if effective, could increase compliance (as it can be administered at the healthcare site), and it is likely to be cheaper. These advantages are important in lower-income countries where women attend antenatal clinics irregularly and where approximately 90% of all preterm deliveries around the world take place (<LINK REF="REF-Villar-1994" TYPE="REFERENCE">Villar 1994</LINK>). The objective of this review was to determine the clinical effectiveness of different durations of treatment for asymptomatic bacteriuria in pregnancy. Only trials comparing a single dose with a short course of four to seven days were found for inclusion in this review.</P>
<P>For the outcome of no cure, meta-analysis of all trials comparing a single dose versus a short course of treatment of the same or different antibiotics showed a wide range of effects (from 50% reduction to a six-fold increase), with no conclusive difference between treatment groups and moderate heterogeneity between trials. The evidence for no cure was graded as of very low quality due to risk of bias concerns in the contributing trials and the imprecision of treatment effects (wide confidence intervals crossing the line of no effect). Fewer babies of low birthweight were born to women who had treatment with a short course of the same microbial agent than to women receiving a single dose, but this result was based on a single study with 714 women and graded to be of moderate quality. A single course of antibiotics also resulted in fewer side effects in 12 trials (1460 women), regardless of the type of antibiotic used; however, this evidence was graded as of low quality due to serious risk of bias concerns in the contributing trials. There were no clear benefits of either a single dose or a short course of antibiotics for any of the following review outcomes, whether the same antibiotic or different antibiotics were used: recurrence (very low quality evidence), pyelonephritis (very low quality evidence), or preterm delivery (moderate quality evidence). Evidence was downgraded due to risk of bias concerns in contributing trials and to imprecision in effect estimates.</P>
<P>When analysis was restricted to two high quality trials, results from the two trials for the outcome of no cure favored short-course treatment of the same microbial agent. No conclusions about cure rates can be drawn for different antimicrobial drugs as this analysis included only one small trial.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-10-25 09:35:16 +0000" MODIFIED_BY="Heather Maxwell">
<P>In general, the trials in this review have several methodological limitations, which makes the interpretation of pooled results difficult. Heterogeneity could presumably be explained by trial design and conduct, but baseline risks of the population studied, differences in the laboratory definition of positive cases (i.e. cultures of &gt; 10,000 or 100,000 CFU/mL), and the different pharmacokinetics and specificities of the antimicrobial agents used could not be ruled out. The <LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK> trial provides about half of the data to the meta-analysis and is methodologically sound. We therefore think that overall, longer duration of treatment is likely to be more effective. However, there is a drawback that non-adherence may be higher with treatments of longer duration.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-10-25 09:36:03 +0000" MODIFIED_BY="Heather Maxwell">
<P>In general, the risk of bias of trials included in this review was largely unclear, with all trials being at high risk of performance bias. Most trials were conducted in the 1980s and 1990s and did not describe methods to avoid selection, detection or performance bias. Only three trials (<LINK REF="STD-Lumbiganon-2009" TYPE="STUDY">Lumbiganon 2009</LINK>; <LINK REF="STD-Masterton-1985" TYPE="STUDY">Masterton 1985</LINK> in the same agent group, and in <LINK REF="STD-Bayrak-2007" TYPE="STUDY">Bayrak 2007</LINK> in the different agent group) were rated as low risk of bias.</P>
<P>The quality of the evidence was assessed using the GRADE approach, see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>. The evidence was graded as: very low quality for the outcomes no cure rate, recurrence of asymptomatic bacteriuria and pyelonephritis; high quality for the outcome low birthweight; moderate quality for preterm delivery; and low quality for side effects. Evidence was downgraded for risk of bias concerns in trials contributing data and for imprecise effect estimates (wide confidence intervals crossing the line of no effect, and in some cases, small studies with few events).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-11-04 11:19:59 +0000" MODIFIED_BY="[Empty name]">
<P>We attempted to minimise bias during the review process by having two people assess the eligibility of studies, assess risk of bias and extract data. We attempted to be as inclusive as possible in our search. The asymmetric funnel plot may suggest publication bias (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) that could result from the small numbers in the included trials. Many trials included in the review were very small. Small trials not only can predispose to publication bias, but also to misleading results as they tend to be conducted and analyzed with less methodological rigor than larger trials and may overestimate the effect of one group. This is of greater concern in equivalence trials where larger sample sizes are required than comparative trials (<LINK REF="REF-Jones-1996" TYPE="REFERENCE">Jones 1996</LINK>). Most trials were not blinded and the risk of performance and detection bias was high, especially for clinical outcomes. Morover, few studies reported efforts to blind the outcome assessment, even those performed at the bacteriology lab. Thus, the poor methodological quality of these trials may obscure any important clinical and laboratory differences between duration of treatment regimens. We explored these issues as a plausible source of heterogeneity by analyzing good and poor quality studies separately.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-10-25 09:38:06 +0000" MODIFIED_BY="Heather Maxwell">
<P>Currently there is a consensus in most settings that asymptomatic bacteriuria during pregnancy should be universally screened and treated (<LINK REF="REF-NICE-2008" TYPE="REFERENCE">NICE 2008</LINK>; <LINK REF="REF-Nicolle-2005" TYPE="REFERENCE">Nicolle 2005</LINK>). However, there are increasing concerns about the emergence of resistant bacterial strains due to high rates of antibiotic use in hospitals, the community and agriculture (<LINK REF="REF-Laxminarayan-2014" TYPE="REFERENCE">Laxminarayan 2014</LINK>). Because of these worries and the lack of convincing evidence for an universal screening and treating policy, some professional associations such as the Dutch Society of Obstetrics and Gynaecology (<LINK REF="REF-NVOG-2011" TYPE="REFERENCE">NVOG 2011</LINK>), and the Dutch General Practitioners Society (<LINK REF="REF-Van-Haaren-2005" TYPE="REFERENCE">Van Haaren 2005</LINK>) recommend screening for asymptomatic bacteriuria only in high-risk women (i.e. women with congenital urinary tract defects, a previous history of urinary tract infections, diabetes mellitus, sickle cell disease or neurological disorders, and reduced immunity). A recently published cohort study from the Netherlands (<LINK REF="REF-Kazemier-2015" TYPE="REFERENCE">Kazemier 2015</LINK>) also questions the universal routine screen-treat-policy for asymptomatic bacteriuria in pregnancy as it showed that, if untreated, asymptomatic bacteriuria had low (although significant) absolute risks for pyelonephritis (2.4% in 208 women with untreated asymptomatic bacteriuria versus 0.6% in 4035 women without bacteriuria). An embedded small randomized controlled trial within this cohort (40 women randomly assigned to nitrofurantoin and 45 to placebo) failed to demonstrate significant differences in the rates of low birthweight, preterm birth or pyelonephritis. However, this study is small, included only very low-risk women and it is uncertain whether these results are generalizable.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-10-25 09:39:00 +0000" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2015-09-25 11:53:19 +0100" MODIFIED_BY="[Empty name]">
<P>The evidence suggests that the standard short course of four- to seven-day treatment regimen for treating asymptomatic bacteriuria in pregnant women is more effective than single-dose regimens. More evidence is needed from large trials measuring important outcomes, such as cure rate. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-10-25 09:39:00 +0000" MODIFIED_BY="Heather Maxwell">
<P>There is a need for a randomized controlled trial designed to test whether shorter courses, i.e. three-day antimicrobial therapy of first-line of choice drug is as effective as longer treatment regimens in prevention of preterm birth, pyelonephritis, and recurrent infection during the index pregnancy. Future trials should, therefore, be designed taking the following factors into account.</P>
<P>(1) Trial size</P>
<P>The trials should be appropriately sized taking into account the 'equivalence' nature of the comparison.</P>
<P>(2) Trial design</P>
<P>Ideally, these trials should be double-blinded and placebo-controlled to prevent bias.</P>
<P>(3) Outcomes</P>
<P>Immediate bacteriological cure (in one to two weeks) is the relevant outcome as related to the treatments under study.</P>
<P>(4) Interventions</P>
<P>Antibiotics should be researched with regard to the following principles:<BR/>(a) the antibiotic of choice should be safe in pregnancy;<BR/>(b) in circumstances where culture and sensitivity are not feasible, empiric, broad-spectrum treatment would be appropriate;<BR/>(c) where susceptibility is known, narrow-spectrum, specific antibiotic treatment would be appropriate.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-11-02 12:13:02 +0000" MODIFIED_BY="[Empty name]">
<P>Edgardo Abalos, who provided comments on the final draft of the 2015 update.</P>
<P>Nancy Medley helped with the editing of the 'Summary of findings' tables and provided feedback to the editorial office. Nancy Medley's work was financially supported by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization. The named authors alone are responsible for the views expressed in this publication.</P>
<P>The World Health Organization and Ivana Lopez, Luciano Mignini, Ariel Rogant retain copyright and all other rights in their respective contributions to the manuscript of this review as submitted for publication, including any revisions or updates to the manuscript which WHO may make from time to time</P>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-10-25 09:39:09 +0000" MODIFIED_BY="Heather Maxwell">
<P>J Villar and AM Gülmezoglu had the idea for the preparation of this review. MT Lydon-Rochelle and A Roganti worked on the background, data extraction and writing the first version of the review.</P>
<P>M Widmer prepared the 2009 update. AM Gulmezoglu review drafts and provided suggestions for revisions. LE Mignini and A Roganti provided comments to the final draft.</P>
<P>I Lopez prepared the 2015 update, commented on and revised all drafts of the update, extracted data, assessed the new included studies, and prepared the 'Summary of findings' tables with the help of Virginia Diaz, Monica Chamilard and Edgardo Abalos. All authors revised and agreed the 2015 update. M Widmer is the guarantor of this review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-10-25 09:39:09 +0000" MODIFIED_BY="Heather Maxwell">
<P>Methods updated to the current standards of the Cochrane Pregnancy and Childbirth Group. 'Summary of findings' tables have been incorporated.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-09-02 10:25:56 +0100" MODIFIED_BY="Frances J Kellie"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-10-22 10:00:19 +0100" MODIFIED_BY="Heather Maxwell">
<STUDIES MODIFIED="2015-04-09 16:01:53 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-09-19 10:02:18 +0100" MODIFIED_BY="Lynn Hampson">
<STUDY DATA_SOURCE="PUB" ID="STD-Anderton-1983" NAME="Anderton 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;[9485]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderton KJ, Abbas AM, Davey A, Ancill RJ</AU>
<TI>High dose, short course amoxycillin in the treatment of bacteriuria in pregnancy</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1983</YR>
<VL>37</VL>
<PG>212-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1983" NAME="Bailey 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;[2530]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey RR, Bishop V, Peddie BA</AU>
<TI>Comparison of single dose with a 5-day course of co-trimoxazole for asymptomatic (covert) bacteriuria of pregnancy</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1983</YR>
<VL>23</VL>
<PG>139-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1986" NAME="Bailey 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;[3025]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey RR, Peddie BA, Bishop V</AU>
<TI>Comparison of single dose with a 5-day course of trimethoprim for asymptomatic (covert) bacteriuria of pregnancy</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1986</YR>
<VL>99</VL>
<PG>501-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bayrak-2007" MODIFIED="2009-10-30 09:49:17 +0000" MODIFIED_BY="[Empty name]" NAME="Bayrak 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-10-30 09:49:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bayrak O, Cimentepe E, Inegol I, Atmaca AF, Duvan CI, Koc A, et al</AU>
<TI>Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimester of pregnancy?</TI>
<SO>International Urogynecology Journal</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>5</NO>
<PG>525-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brumfitt-1982" NAME="Brumfitt 1982" YEAR="">
<REFERENCE NOTES="&lt;p&gt;10599&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brumfitt W, Hamilton Miller JM, Franklin IN, Anderson FM, Brown GM</AU>
<TI>Conventional and two dose amoxycillin treatment of bacteriuria in pregnancy and recurrent bacteriuria: a comparative study</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1982</YR>
<VL>10</VL>
<PG>239-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Estebanez-2009" MODIFIED="2011-06-17 10:55:03 +0100" MODIFIED_BY="Lynn Hampson" NAME="Estebanez 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-17 10:54:55 +0100" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Estebanez A, Pascual R, Gil V, Ortiz F, Santibanez M, Perez Barba C</AU>
<TI>Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy</TI>
<SO>European Journal of Clinical Microbiology &amp; Infectious Diseases</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>12</NO>
<PG>1457-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerstner-87_x002d_89" MODIFIED="2011-09-19 10:02:18 +0100" MODIFIED_BY="[Empty name]" NAME="Gerstner 87-89" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;[5037]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerstner GJ, Muller G, Nahler G</AU>
<TI>Amoxicillin in the treatment of asymptomatic bacteriuria in pregnancy: a single dose of 3g amoxicillin vs a 4-day course of 3 doses 750mg amoxicillin</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1989</YR>
<VL>27</VL>
<PG>84-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-09-19 10:02:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[4149]&lt;/p&gt;" NOTES_MODIFIED="2011-09-19 10:02:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gertsner GJ, Muller G, Nahler G</AU>
<TI>Amoxicillin in the treatment of asymptomatic bacteriuria in pregnancy--3g single dose versus 3 times 750mg 4-day therapy</TI>
<TO>Amoxicillin zur Behandlung der asymptomatischen Bakteriurie in der Schwangerschaft--3g Einmal-versus 3 x 750mg 4-Tagestherapie</TO>
<SO>Zeitschrift fur Geburtshilfe und Perinatologie</SO>
<YR>1987</YR>
<VL>191</VL>
<NO>5</NO>
<PG>202-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lumbiganon-2009" MODIFIED="2011-09-19 10:02:02 +0100" MODIFIED_BY="[Empty name]" NAME="Lumbiganon 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-09-19 10:02:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lumbiganon P, Villar J, Laopaiboon M, Widmer M, Thinkhamrop J, Carroli G, et al</AU>
<TI>One-day compared with 7-day nitrofurantoin for asymptomatic bacteriuria in pregnancy: a randomized controlled trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2009</YR>
<VL>113</VL>
<NO>2 Pt 1</NO>
<PG>339-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-24 12:41:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Multicentre randomized placebo-controlled trial to evaluate the effectiveness of one-day versus seven-day course of nitrofurantoin for the treatment of asymptomatic bacteriuria</TI>
<SO>World Health Organization (www.who.int/reproductive-health/publications/highlights/hights_hrp_2005.html)</SO>
<YR>(accessed 25 April 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masterton-1985" NAME="Masterton 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;[769]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masterton RG, Evans DC, Strike PW</AU>
<TI>Single-dose amoxycillin in the treatment of bacteriuria in pregnancy and the puerperium-a controlled clinical trial</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1985</YR>
<VL>92</VL>
<PG>498-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsen-1989" NAME="Olsen 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;[5296]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsen L, Nielsen IK, Zachariassen A, Sederberg-Olsen J, Frimodt-Moller N</AU>
<TI>Single-dose vs six-day therapy with sulfamethizole for asymptomatic bacteriuria during pregnancy</TI>
<SO>Danish Medical Bulletin</SO>
<YR>1989</YR>
<VL>36</VL>
<PG>486-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pregazzi-1987" NAME="Pregazzi 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pregazzi R, Mazzatenta E, Bouche C</AU>
<TI>Single-dose antibiotic therapy of asymptomatic bacteriuria in pregnancy. Results and complications</TI>
<SO>Minerva Ginecologica</SO>
<YR>1987</YR>
<VL>39</VL>
<PG>289-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reeves-1975" NAME="Reeves 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;[3073]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reeves DS</AU>
<TI>Laboratory and clinical studies with sulfametopyrazine as a treatment for bacteriuria in pregnancy</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1975</YR>
<VL>1</VL>
<PG>171-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thoumsin-1990" NAME="Thoumsin 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thoumsin H, Aghayan M, Lambotte R</AU>
<TI>Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: preliminary results</TI>
<SO>Infection</SO>
<YR>1990</YR>
<VL>18</VL>
<PG>S94-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-04-09 16:00:49 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adelson-1992" NAME="Adelson 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;[7852]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adelson MD, Graves WL, Osborne NG</AU>
<TI>Treatment of urinary infections in pregnancy using single dose vs 10 day dosing</TI>
<SO>Journal of the National Medical Association</SO>
<YR>1992</YR>
<VL>84</VL>
<PG>73-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bint-1979" NAME="Bint 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bint A, Bullock D, Reeves D, Wilkinson P</AU>
<TI>A comparative trial of pivmecillinam and ampicillin in bacteriuria in pregnancy</TI>
<SO>Infection</SO>
<YR>1979</YR>
<VL>7</VL>
<PG>290-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brumfitt-1973" NAME="Brumfitt 1973" YEAR="">
<REFERENCE NOTES="&lt;p&gt;10601&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brumfitt W, Pursell R</AU>
<TI>Trimethoprim - sulfamethoxazole in treatment of bacteriuria in women</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1973</YR>
<VL>128 Suppl</VL>
<PG>S657-S663</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell_x002d_Brown-1983" NAME="Campbell-Brown 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell-Brown M, Mc Fadyen IR</AU>
<TI>Bacteriuria in pregnancy treated with a single dose of cephalexin</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1983</YR>
<VL>90</VL>
<NO>11</NO>
<PG>1054-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-1975" NAME="Davies 1975" YEAR="">
<REFERENCE NOTES="&lt;p&gt;10600&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies BI, Mummery RV, Brummfitt W</AU>
<TI>Ampicillin, carbenicillin indanyl ester, and nifurantel in treatment of urinary infection in domiciliary practice</TI>
<SO>British Journal of Urology</SO>
<YR>1975</YR>
<VL>47</VL>
<PG>335-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Cecco-1987" NAME="De Cecco 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;[3582]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Cecco L, Ragni N</AU>
<TI>Urinary tract infections in pregnancy: monuril single-dose treatment vs traditional therapy</TI>
<SO>European Urology</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>108-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1982" NAME="Harris 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;[3052]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris RE, Gilstrap LC, Pretty A</AU>
<TI>Single-dose antimicrobial therapy for asymptomatic bacteriuria during pregnancy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1982</YR>
<VL>59</VL>
<PG>546-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jakobi-1987" NAME="Jakobi 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jakobi P, Neiger R, Merzbach D, Paldi E</AU>
<TI>Single-dose antimicrobial therapy in the treatment of asymptomatic bacteriuria in pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1987</YR>
<VL>156</VL>
<NO>5</NO>
<PG>1148-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McFadyen-1987" NAME="McFadyen 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McFadyen IR, Campbell BM, Stephenson M, Seal DV</AU>
<TI>Single-dose treatment of bacteriuria in pregnancy</TI>
<SO>European Urology</SO>
<YR>1987</YR>
<VL>13 Suppl 1</VL>
<PG>22-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pathak--1969" NAME="Pathak  1969" YEAR="">
<REFERENCE NOTES="&lt;p&gt;10602&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pathak UN, Tang K, Williams LL, Stuart KL</AU>
<TI>Bacteriuria of pregnancy: results of treatment</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1969</YR>
<VL>120</VL>
<PG>91-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedler-1985" NAME="Pedler 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedler S, Bint A</AU>
<TI>Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1985</YR>
<VL>27</VL>
<PG>508-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rafalsky-2013" MODIFIED="2015-04-09 16:00:49 +0100" MODIFIED_BY="[Empty name]" NAME="Rafalsky 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-04-09 15:52:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rafal'skii VV, Dovgan' EV, Kozyrev IuV, Gustovarova TA, Khlybova SV, Novoselova AV, et al</AU>
<TI>The efficacy and safety of cefixime and amoxicillin/clavulanate in the treatment of asymptomatic bacteriuria in pregnant women: a randomized, prospective, multicenter study</TI>
<SO>Urologiia</SO>
<YR>2013</YR>
<VL>5</VL>
<NO>24</NO>
<PG>26-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-04-09 16:00:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rafalskiy V, Dovgan E, Kozyrev Y, Gustovarova T, Khlybova S, Novoselova A, et al</AU>
<TI>Cefixime vs. amoxicillin/clavulanate in pregnant women with asymptomatic bacteriuria: Multicentre randomised study</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>Suppl s3</NO>
<PG>425-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robertson-1968" NAME="Robertson 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;[540]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robertson JG, Livingstone JRB, Isdale MH</AU>
<TI>The management and complications of asymptomatic bacteriuria in pregnancy</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Commonwealth</SO>
<YR>1968</YR>
<VL>75</VL>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanderson-1984" NAME="Sanderson 1984" YEAR="">
<REFERENCE NOTES="&lt;p&gt;10598&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanderson P, Menday P</AU>
<TI>Pivmecillinam for bacteriuria in pregnancy</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1984</YR>
<VL>13</VL>
<PG>383-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whalley-1977" NAME="Whalley 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;[3089]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whalley PJ, Cunningham FG</AU>
<TI>Short-term vs continuous antimicrobial therapy for asymptomatic bacteriuria in pregnancy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1977</YR>
<VL>49</VL>
<PG>262-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zinner-1990" NAME="Zinner 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;[6482]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zinner S</AU>
<TI>Fosfomycin trometamol versus pipemidic acid in the treatment of bacteriuria during pregnancy</TI>
<SO>Chemotherapy</SO>
<YR>1990</YR>
<VL>36</VL>
<PG>50-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-04-09 16:01:53 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2009-10-30 09:36:23 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-22 10:00:19 +0100" MODIFIED_BY="Heather Maxwell">
<ADDITIONAL_REFERENCES MODIFIED="2015-10-22 10:00:19 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Andrews-1992" MODIFIED="2015-10-22 09:55:32 +0100" MODIFIED_BY="Heather Maxwell" NAME="Andrews 1992" TYPE="BOOK_SECTION">
<AU>Andrews WW, Gilstrap LC</AU>
<TI>Urinary tract infections</TI>
<SO>Principles and Practice of Medical Therapies in Pregnancy</SO>
<YR>1992</YR>
<PG>913-7</PG>
<ED>Gleicher N</ED>
<PB>Appleton and Lange, Norwalk, Co</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davison-1992" MODIFIED="2015-10-22 09:54:47 +0100" MODIFIED_BY="Heather Maxwell" NAME="Davison 1992" TYPE="BOOK_SECTION">
<AU>Davison JM, Lindheimer MD</AU>
<TI>Chronic renal disease</TI>
<SO>Principles and Practice of Medical Therapies in Pregnancy</SO>
<YR>1992</YR>
<PG>928-32</PG>
<ED>Gleicher N</ED>
<PB>Appleton and Lange, Norwalk, Co</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldenberg-2000" MODIFIED="2015-05-29 17:14:19 +0100" MODIFIED_BY="[Empty name]" NAME="Goldenberg 2000" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg RL, Hauth JC, Andrews WW</AU>
<TI>Mechanisms of disease: intrauterine infection and preterm delivery</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>20</NO>
<PG>1500-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-04-27 15:51:52 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1996" NAME="Jones 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jones B, Jarvis P, Lewis JA, Ebbutt AF</AU>
<TI>Trials to assess equivalence: the importance of rigorous methods</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>36-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kazemier-2015" MODIFIED="2015-10-16 08:55:20 +0100" MODIFIED_BY="[Empty name]" NAME="Kazemier 2015" TYPE="OTHER">
<AU>Kazemier BM, Koningstein FN, Schneeberger C, Ott A, Bossuyt PM, de Miranda E, et al</AU>
<TI>Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2015 August. [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laxminarayan-2014" MODIFIED="2015-10-15 14:40:48 +0100" MODIFIED_BY="[Empty name]" NAME="Laxminarayan 2014" TYPE="JOURNAL_ARTICLE">
<AU>Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al</AU>
<TI>Antibiotic resistance - the need for global solutions</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2013</YR>
<VL>13</VL>
<NO>2</NO>
<PG>1057-98</PG>
<IDENTIFIERS MODIFIED="2015-10-03 00:44:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Meis-1995a" MODIFIED="2015-10-22 09:56:21 +0100" MODIFIED_BY="Heather Maxwell" NAME="Meis 1995a" TYPE="JOURNAL_ARTICLE">
<AU>Meis PJ, Michielutte R, Peters TJ, Wells HB, Sands E, Coles EC, et al</AU>
<TI>Factors associated with preterm birth in Cardiff, Wales. I. Univariable and multivariable analysis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>173</VL>
<PG>590-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meis-1995b" MODIFIED="2015-10-22 09:56:38 +0100" MODIFIED_BY="Heather Maxwell" NAME="Meis 1995b" TYPE="JOURNAL_ARTICLE">
<AU>Meis PJ, Michielutte R, Peters TJ, Wells HB, Sands E, Coles EC, et al</AU>
<TI>Factors associated with preterm birth in Cardiff, Wales. II. Indicated and spontaneous preterm birth</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>173</VL>
<PG>597-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2008" MODIFIED="2015-10-03 10:19:35 +0100" MODIFIED_BY="Sonja L Henderson" NAME="NICE 2008" TYPE="BOOK">
<AU>National Institute for Health and Clinical Excellence: Guidance</AU>
<SO>Antenatal Care: Routine Care for the Healthy Pregnant Woman</SO>
<YR>2008</YR>
<ED>Jane Moody</ED>
<PB>RCOG Press</PB>
<CY>London</CY>
<IDENTIFIERS MODIFIED="2015-10-03 01:13:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Nicolle-2005" MODIFIED="2015-10-03 10:22:17 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Nicolle 2005" TYPE="JOURNAL_ARTICLE">
<AU>Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM</AU>
<TI>Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>5</NO>
<PG>643-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NVOG-2011" MODIFIED="2015-10-16 09:05:02 +0100" MODIFIED_BY="[Empty name]" NAME="NVOG 2011" TYPE="BOOK">
<AU>Dutch Society of Obstetrics and Gynecology</AU>
<SO>NVOG Guideline: Urinary Tract Infection in Pregnancy</SO>
<YR>2011</YR>
<PB>NVOG</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ramsey-2000" MODIFIED="2015-10-22 09:57:42 +0100" MODIFIED_BY="Heather Maxwell" NAME="Ramsey 2000" TYPE="BOOK_SECTION">
<AU>Ramsey P, Goldenberg R</AU>
<TI>Maternal Infections and their consequences</TI>
<SO>Congenital and Perinatal Infections. Prevention, Diagnosis and Treatment</SO>
<YR>2000</YR>
<PG>32-63</PG>
<EN>1st</EN>
<ED>Newell &amp; McIntyre</ED>
<PB>Cambridge University Press</PB>
<CY>Cambridge</CY>
<IDENTIFIERS MODIFIED="2015-05-29 16:54:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-09-11 11:42:53 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Romero-1989" NAME="Romero 1989" TYPE="JOURNAL_ARTICLE">
<AU>Romero R, Oyarzun E, Mazor M, Sirtori M, Hobbins JC, Bracken M</AU>
<TI>Meta-analysis of the relationship between asymptomatic bacteriuria and preterm delivery/low birth weight</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1989</YR>
<VL>73</VL>
<PG>576-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rouse-1995" NAME="Rouse 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rouse DJ, Andrews WW, Goldenberg RL, Owen J</AU>
<TI>Screening and treatment of asymptomatic bacteriuria of pregnancy to prevent pyelonephritis: a cost-effectiveness and cost-beneficial analysis</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1995</YR>
<VL>86</VL>
<PG>119-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smaill-2015" MODIFIED="2015-10-22 10:00:19 +0100" MODIFIED_BY="Heather Maxwell" NAME="Smaill 2015" TYPE="COCHRANE_REVIEW">
<AU>Smaill FM, Vazquez JC</AU>
<TI>Antibiotics for asymptomatic bacteriuria in pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2015-09-24 11:05:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-24 11:05:55 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000490.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sweet-1977" NAME="Sweet 1977" TYPE="JOURNAL_ARTICLE">
<AU>Sweet RL</AU>
<TI>Bacteriuria and pyelonephritis during pregnancy</TI>
<SO>Seminars in Perinatology</SO>
<YR>1977</YR>
<VL>1</VL>
<PG>25-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Haaren-2005" MODIFIED="2015-10-16 09:00:01 +0100" MODIFIED_BY="[Empty name]" NAME="Van Haaren 2005" TYPE="JOURNAL_ARTICLE">
<AU>Van Haaren KAM, Visser HS, Van Vliet S, Timmermans AE, Yadava R, Geerlings SE, et al</AU>
<TI>Guideline of the Dutch College of General Practitioners on urinary tract infections: second revision</TI>
<TO>NHG-standaard urineweginfecties: 2e herziening</TO>
<SO>Huisarts en Wetenschap</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>10</NO>
<PG>341-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-1994" NAME="Villar 1994" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Ezcurra EJ, Gurtner de la Fuente V, Campodonico L</AU>
<TI>Preterm delivery syndrome - the unmet need</TI>
<SO>Research and Clinical Forums</SO>
<YR>1994</YR>
<VL>16</VL>
<PG>9-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-1997" MODIFIED="2011-09-15 03:14:04 +0100" MODIFIED_BY="[Empty name]" NAME="Villar 1997" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Gülmezoglu AM, De Onis M</AU>
<TI>Nutritional and antimicrobial interventions to prevent preterm birth: an overview of randomized control trials</TI>
<SO>Obstetrical &amp; Gynecological Survey</SO>
<YR>1998</YR>
<VL>53</VL>
<PG>575-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-1989" MODIFIED="2015-10-16 09:06:37 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 1989" TYPE="BOOK_SECTION">
<AU>Wang E, Smaill F</AU>
<TI>Infection in pregnancy</TI>
<SO>Effective Care in Pregnancy and Childbirth</SO>
<YR>1989</YR>
<PG>534-7</PG>
<ED>Chalmers I, Enkin MW, Keirse MJNC</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-10-22 09:51:26 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Smaill-1992a" NAME="Smaill 1992a" TYPE="OTHER">
<AU>Smaill F</AU>
<TI>Single dose vs 4-7 day antibiotic for bacteriuria. [revised 02 April 1992]</TI>
<SO>In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2, Oxford: Update Software; 1995</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smaill-1992b" NAME="Smaill 1992b" TYPE="OTHER">
<AU>Smaill F</AU>
<TI>Single dose vs 7-day course of antibiotics for bacteriuria. [revised 02 April 1992]</TI>
<SO>In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration. Issue 2, Oxford: Update Software; 1995</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smaill-1992c" NAME="Smaill 1992c" TYPE="OTHER">
<AU>Smaill F</AU>
<TI>Two week vs continuous antibiotic for bacteriuria. [revised 02 April 1992]</TI>
<SO>In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration. Issue 2, Oxford: Update Software; 1995</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-2000" MODIFIED="2015-10-22 09:51:26 +0100" MODIFIED_BY="Heather Maxwell" NAME="Villar 2000" TYPE="COCHRANE_REVIEW">
<AU>Villar J, Widmer M, Lydon-Rochelle M, Gülmezoglu AM, Roganti A</AU>
<TI>Duration of treatment for asymptomatic bacteriuria during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-10-22 09:51:00 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2015-10-22 09:51:00 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD000491"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Widmer-2011" MODIFIED="2014-09-11 11:41:16 +0100" MODIFIED_BY="[Empty name]" NAME="Widmer 2011" TYPE="COCHRANE_REVIEW">
<AU>Widmer M, Gülmezoglu AM, Mignini L, Roganti A</AU>
<TI>Duration of treatment for asymptomatic bacteriuria during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2014-09-11 11:41:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-09-11 11:41:16 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000491.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-06-17 10:57:18 +0100" MODIFIED_BY="Lynn Hampson"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-10-26 09:29:01 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-10-26 09:29:01 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-07-01 14:38:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderton-1983">
<CHAR_METHODS>
<P>Alternate allocation. It was unclear whether the following criteria were met: blinding of outcome assessment, measurement of contamination of control group, assessment of co-interventions, any deviation from protocol. Providers and pregnant women were not blinded. Informed consent was obtained. No description of sample size or power calculation was provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-01 14:38:22 +0100" MODIFIED_BY="[Empty name]">
<P>67 women enrolled in study. Setting: out-patient clinic in United Kingdom. Inclusion criteria: pregnant women &gt; 16 years; confirmed asymptomatic bacteriuria with 2 consecutive positive bacteriologic count of identical organisms; urine culture sensitive to amoxicillin. Exclusion criteria: allergic to penicillin or cephalosporins; inability to take oral medications; requires parenteral antibiotics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental group: amoxicillin 3 g x 2 doses.<BR/>Control group: amoxicillin 250 mg 3 times daily x 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-14 19:24:53 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical outcomes: medication side effects.<BR/>Laboratory outcomes: rate of 'no cure'.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-14 19:25:12 +0100" MODIFIED_BY="[Empty name]">
<P>Type of healthcare provider: unknown.<BR/>Attrition bias: no loss to follow-up from experimental group 0/33; loss of follow-up for control group 2/34 (6%).<BR/>Authors state that the 'majority' of study participants had asymptomatic bacteriuria; no description of distribution or breakdown by outcomes is provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-26 09:29:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bailey-1983">
<CHAR_METHODS MODIFIED="2015-10-26 09:29:01 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial. Method of randomization not described. Envelopes containing group assignment were used (no information re: sealed/opaque). No further description was provided regarding allocation. It was unclear whether the following criteria were met: blinding of outcome assessment, measurement of contamination of control group, assessment of co-interventions, any deviation from protocol. Providers and pregnant women were not blinded. Consent process not described. No description of sample size or power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-22 17:07:44 +0100" MODIFIED_BY="Heather Maxwell">
<P>44 women enrolled in study. Setting: out-patient clinic in New Zealand. Inclusion criteria: pregnant women &lt; 30 weeks estimated gestational age; confirmed asymptomatic bacteriuria with mid-stream urine culture of bacterial count &gt; 100,000, and second urine specimen by suprapubic bladder aspiration showing infection regardless of bacterial count; urine culture was sensitive to co-trimoxazole. Exclusion criteria: allergic to sulfonamides or co-trimoxazole.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental group: co-trimoxazole 1.92 g x 1 dose.<BR/>Control group: co-trimoxazole 0.96 g twice daily x 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-14 19:26:39 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical outcomes: preterm delivery, pyelonephritis, medication side effects.<BR/>Laboratory outcomes: no cure, recurrent asymptomatic bacteriuria.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-14 19:26:49 +0100" MODIFIED_BY="[Empty name]">
<P>Type of healthcare provider: unknown.<BR/>Attrition bias: no loss to follow-up from experimental group 0/24; 2/20 (10%) women lost to follow-up from control group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-29 20:32:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bailey-1986">
<CHAR_METHODS MODIFIED="2015-05-29 20:32:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial. Method of randomization not described. Envelopes containing group assignment were used (no information re: sealed/opaque). No further description was provided regarding allocation. It was unclear whether the following criteria were met: blinding of outcome assessment, measurement of contamination of control group, assessment of co-interventions, any deviation from protocol. Providers and pregnant women were not blinded. Consent process not described. No description of sample size or power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-14 19:27:41 +0100" MODIFIED_BY="[Empty name]">
<P>60 women enrolled in study. Population race/ethnicity 28% 'Polynesian'. Setting: out-patient clinic in New Zealand. Inclusion criteria: pregnant women 16-30 weeks' estimated gestational age; confirmed asymptomatic bacteriuria with mid-stream urine culture of bacterial count &gt; 100,000, and second urine specimen by suprapubic bladder aspiration showing infection regardless of bacterial count. Exclusion criteria: not described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental group: trimethoprim 600 mg x 1 dose.<BR/>Control group: trimethoprim 300 mg once daily x 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-14 19:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical outcomes: preterm delivery, pyelonephritis, medication side effects.<BR/>Laboratory outcomes: no cure, recurrent asymptomatic bacteriuria.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-14 19:28:08 +0100" MODIFIED_BY="[Empty name]">
<P>Type of healthcare provider: unknown.<BR/>Minimal attrition bias: no loss to follow-up from experimental group 0/30; 2/30 (7%) women lost to follow-up from control group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-22 17:12:56 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Bayrak-2007">
<CHAR_METHODS MODIFIED="2015-10-22 17:12:29 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomized controlled trial. 90 pregnant women were randomized to receive either a single dose fosfomycin trometamol or a 5-day course of cefuroxime axetyl. Pregnant women were not blinded to treatment assignment. It was unclear whether the following criteria were met: measurement of contamination of control group, assessments of co-interventions. Power calculation described, sample size calculation conducted.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 22:12:11 +0100" MODIFIED_BY="[Empty name]">
<P>90 women were enrolled in the trial. Setting: women attending the department of Urology and ANC clinics of Faith University, Ankora, Turkey. 1 patient in the fosfomycin trometamol group and 5 patients in the cefuroxime axetyl group were lost to follow-up and excluded from the trial. Inclusion criteria: pregnant women in the second trimester of gestation, confirmed asymptomatic bacteriuria with 2 consecutive clean-catch urine specimens yielding positive cultures of the same uropathogen. Exclusion criteria: gravidas presenting leukocytosis, fever, urolithiasis, lower back pain, previous urologic surgery, anomalies of the urinary tract.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-22 17:12:56 +0100" MODIFIED_BY="Heather Maxwell">
<P>Experimental group: single dose of 3 g fosfomycin trometamol.</P>
<P>Control group: cefuroxime axetyl 250 mg twice a day for 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-14 19:28:45 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical outcome: side effects.</P>
<P>Laboratory outcome: bacteriological eradication of uropathogens.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-22 17:11:20 +0100" MODIFIED_BY="Heather Maxwell">
<P>Cure rates are informed only as percentages. No ratios are informed.</P>
<P>Side effects are informed in percentages. No risk ratios nor confidence intervals provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 22:12:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brumfitt-1982">
<CHAR_METHODS>
<P>Randomized controlled trial. Randomization tables were used to allocate participants. Unclear measurement of contamination of control group, assessment of co-interventions, any deviation from protocol. Providers and pregnant women were not blinded. No description of sample size or power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 22:12:49 +0100" MODIFIED_BY="[Empty name]">
<P>54 women enrolled in a out-patient antenatal clinic in England, UK.<BR/>Inclusion criteria: pregnant women with culture confirmed asymptomatic bacteriuria during routine screening.<BR/>Exclusion criteria: allergic to penicillin, infecting organisms were not sensitive to ampicillin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental group: oral amoxicillin 3 g x 2 doses during 1 day.<BR/>Control group: oral amoxicillin 250 mg 3 times daily x 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-14 19:29:17 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical outcomes: birthweight, medication side effects.<BR/>Laboratory outcome: cultures cure rates at 2 and 6 weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>24% were symptomatic in both groups, 65% were in the second trimester.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-22 17:14:20 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Estebanez-2009">
<CHAR_METHODS MODIFIED="2011-06-13 07:35:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, prospective, longitudinal, unblinded trial. Allocation concealment done using random number tables. Method of randomization not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-22 17:14:20 +0100" MODIFIED_BY="Heather Maxwell">
<P>131 pregnant women enrolled in the study. Setting: out-patient clinic in Spain. Inclusion criteria: pregnant women with asymptomatic bacteriuria (&#8807; 100,000 CFU/mL of the same micro-organism in two consecutive cultures) without fever or symptoms of UTI. Exclusion criteria: having taken antibiotics 14 days prior to taking the culture for any reason other than having UTI; allergy to penicillins; high-risk pregnancy; admitted to hospital; impossibility of performing follow-up; anomalies in the urinary tract; infection due to microorganisms resistant to either of the 2 antibiotics and symptomatic UTI.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-11 11:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental group: fosfomycin 3 g x 1 dose.</P>
<P>Control group: amoxicillin-clavulanate 500 mg/125 mg tablets every 8 hours for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-14 19:29:45 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical outcomes: microbiological cure, recurrences, reinfection, persistences, secondary effects, and therapeutic compliance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-11 11:07:44 +0100" MODIFIED_BY="[Empty name]">
<P>Authors reported that there were no losses to follow-up, although outcomes reported for 109 out of 131 women recruited.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-14 19:30:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerstner-87_x002d_89">
<CHAR_METHODS>
<P>Randomized controlled trial. Allocation concealment not described. Allocation to treatment done in blocks of 10-5 per treatment group. It was unclear whether the following criteria were met: blinding of outcome assessment, measurement of contamination of control group, assessment of co-interventions, any deviation from protocol. Providers and pregnant women were not blinded. Informed consent was obtained. No description of sample size or power calculation was provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-26 12:46:13 +0000" MODIFIED_BY="[Empty name]">
<P>91 women (53 single dose, 38 longer course) enrolled in study. Setting: multicenter out-patient clinic in Austria. Inclusion criteria: pregnant women; confirmed asymptomatic bacteriuria with mid-stream urine culture of bacterial count &gt; 100,000 and bladder catheterization with bacterial count &gt; 10,000 diagnosed with the dip-slide method; urine culture sensitive to amoxicillin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental group: amoxicillin 3 g x single dose.<BR/>Control group: amoxicillin 750 mg 3 times daily x 4 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-14 19:30:20 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical outcomes: medication side effects.<BR/>Laboratory outcomes: 'no cure', recurrence of asymptomatic bacteriuria after 1 and 4 weeks following therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-14 19:30:29 +0100" MODIFIED_BY="[Empty name]">
<P>Healthcare providers: physicians and nurses.<BR/>Attrition bias: loss to follow-up from experimental group was 7/53 (13%); loss to follow-up from control group was 10/38 (26%).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-22 17:16:21 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Lumbiganon-2009">
<CHAR_METHODS MODIFIED="2015-10-22 17:15:47 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomized, double-blind, placebo-controlled non-inferiority trial. Pregnant women were randomly allocated to receive either a 1-day or a 7-day course of nitrofurantoin. Compliance was of 98% in both groups. Power calculation described, sample size calculation conducted. Assessment of co-interventions was done. Deviations from protocol were described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-22 17:16:21 +0100" MODIFIED_BY="Heather Maxwell">
<P>778 women from ANC clinics from Thailand, The Phillippines, Vietnam and Argentina were enrolled in the trial. 9 women in the 1-day regimen and 10 women in the 7-day regimen were lost to follow-up. Sociodemographic characteristics of each group were similar at entry. Inclusion criteria: pregnant women at gestational age 12-32 weeks with no symptoms of urinary tract infection. Exclusion criteria: history of urinary tract infection during current pregnancy, under steroids and/or antibiotic treatment, presence of any hematological disease including glucose-6-phosphate dehydrogenase deficiency.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-11 11:09:18 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental group: 1-day nitrofurantoin 100 mg twice a day.</P>
<P>Control group: 7-day nitrofurantoin 100 mg twice a day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-26 12:46:53 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical outcomes: incidence of symptomatic urinary tract infection, pyelonephritis, preterm delivery, low birthweight, adverse effects.</P>
<P>Laboratory outcomes: bacteriologic cure after antibiotic treatment assessed by a urine culture 14 days after the initiation of the treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-11 11:09:24 +0100" MODIFIED_BY="[Empty name]">
<P>Eligible, but not randomized women reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-22 10:27:52 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Masterton-1985">
<CHAR_METHODS>
<P>Randomized controlled trial. Allocation by computer-generated randomization. There was blinding of outcome assessment and providers (treatment allocation by clinic secretary). Pregnant women were not blinded. It was unclear whether the following criteria were met: measurement of contamination of control group, assessment of co-interventions, any deviation from protocol. Informed consent was obtained. Power calculation described; sample size calculation conducted, however, sample size achieved inadequate due to limited trial period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-22 10:27:52 +0100" MODIFIED_BY="Heather Maxwell">
<P>102 women were enrolled in study, 90 completed the protocol, and 62 women were analyzed as the subgroup 'antenatal asymptomatic bacteriuria'. Wives (British nationality) of servicemen from United Kingdom stationed in Germany. Setting: out-patient clinic. Inclusion criteria: pregnant women 28-36 weeks' estimated gestational age; confirmed asymptomatic bacteriuria with 2 consecutive urine cultures of bacterial count &#8807; 100,000 colonies/mL urine; urine culture was ampicillin sensitive. Exclusion criteria: pyelonephritis; history of drug sensitivity to beta-lactam agents; or use of antibiotics within last 2 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental group: amoxicillin 3 g single dose.<BR/>Control group: ampicillin 500 mg 4 times daily x 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Laboratory outcomes: 'no cure', recurrent asymptomatic bacteriuria. Re-infection assessed at 1 week and 6 weeks after treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Type of healthcare provider: general practitioners and obstetricians.<BR/>No attrition bias: no women lost from experimental group 0/39, or from control group 0/23.<BR/>Ampicillin rather than amoxicillin was chosen because it is standard in this hospital.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-22 17:19:38 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Olsen-1989">
<CHAR_METHODS>
<P>Randomized controlled trial. No description of method for generation and concealment of treatment. Providers and pregnant women were not blinded. It was unclear whether the following criteria were met: blinding of outcome assessment, measurement of contamination of control group, assessment of co-interventions, any deviation from protocol. Informed consent was obtained. No description of sample size or power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-22 17:19:38 +0100" MODIFIED_BY="Heather Maxwell">
<P>41 women enrolled in study. Setting: out-patient clinic in Denmark. Inclusion criteria: pregnant women &lt; 36 weeks estimated gestational age; confirmed asymptomatic bacteriuria with 2 consecutive urine cultures of bacterial count &#8807; 100,000 colonies/mL urine; urine culture was sensitive to sulfamethizole. Exclusion criteria: signs of urinary tract infection; chronic disease of the genitourinary tract; history of more than 2 urinary tract infections in previous 12 months; threatening preterm labour &gt; 26 weeks estimated gestational age; allergy to sulfonamides; antibiotic therapy for any reason within 3 weeks prior to study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental group: sulfamethizole 2 g x single dose.<BR/>Control group: sulfamethizole 1 g twice daily x 6 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-14 19:34:09 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical outcomes: medication side effects.<BR/>Laboratory outcomes: 'no cure', recurrence of asymptomatic bacteriuria.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-14 19:34:14 +0100" MODIFIED_BY="[Empty name]">
<P>Type of healthcare provider: not described.<BR/>Attrition bias: no women lost from experimental group 0/15; 2/26 (8%) women lost to follow-up from control group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-22 17:20:25 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Pregazzi-1987">
<CHAR_METHODS MODIFIED="2011-09-15 02:56:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial. 44 pregnant women were divided into 2 groups: 1 treated traditionally and the other with single dose. Allocation to treatment is not described. Pregnant women were not blinded. Consent process is not described. It was unclear whether the following criteria were met: measurement of contamination of control group, assessment of co-interventions, any deviation from protocol. The traditional protocol produced an immediate response in 86.4% of the cases demonstrating its superiority over the single-dose treatment that brought success in 54.5% of the cases.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-22 17:20:25 +0100" MODIFIED_BY="Heather Maxwell">
<P>44 women enrolled in the study. Setting: out-patient clinic in Trieste University, Italy. October 1980 to December 1985. Inclusion criteria: pregnant women aged 17-35 years old, confirmed asymptomatic bacteriuria with positive bacteriological count &gt; 100,000 CFU/mL. Exclusion criteria: 1st bacteriological count &lt; 100,000 CFU/mL or 2nd bacteriological count &gt; 100,000 CFU/mL but different micro-organism comparing with the first one.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental group: single dose of amoxicillin 3 g, or ampicillin 3.5 g, or trimethoprim 320 mg, or sulfamethoxazole 1600 mg, or cephalexin 3 g. Control group: 2-4 times daily x 1-2 weeks of the antibiotics named in the experiment group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-15 02:57:10 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical outcomes: medication side effects. Laboratory outcomes: no cure rate, recurrent asymptomatic bacteriuria.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-15 02:57:15 +0100" MODIFIED_BY="[Empty name]">
<P>Type of health provider: not described. Attrition bias: no description of loss to follow-up from experimental group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-22 17:21:29 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Reeves-1975">
<CHAR_METHODS>
<P>Generation of allocation sequence was by alternation. It was unclear whether the following criteria were met: measurement of contamination of control group, assessment of co-interventions, any deviation from protocol. Blinding of outcome assessment, providers and pregnant women was not done. Consent process not described. No description of sample size or power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-22 17:21:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>100 women enrolled in study. Setting: antenatal clinics in England. Inclusion criteria: pregnant women attending the bacteriuria clinic; confirmed bacteriuria with 2 consecutive urine cultures of bacterial count greater than or equal to 100,000 colonies/mL urine; urine culture was sensitive to sulfonamides. Exclusion criteria: not described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-22 17:21:09 +0100" MODIFIED_BY="Heather Maxwell">
<P>Experiment group: sulfonamide sulfametopyrazine 2 g single dose, orally in 50 mL of water in the clinic.<BR/>Control group: sulfadimidine 1 g 4 times daily x 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-22 17:21:29 +0100" MODIFIED_BY="Heather Maxwell">
<P>Clinical outcome: medication side effects.<BR/>Laboratory outcome: 'no cure', 2 and 6 weeks after the first dose. Growth of different bacteria considered re-infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-15 02:57:53 +0100" MODIFIED_BY="[Empty name]">
<P>Type of healthcare provider: physicians.<BR/>Attrition bias: loss to follow-up from experimental group 5/54 (9% ); loss to follow-up from control group 6/46 (13%).<BR/>Unable to abstract data on 'recurrent asymptomatic bacteriuria': Reeves's operational definition of cure rate at 6 weeks was incomparable to the definition of recurrent asymptomatic bacteriuria used for review. No differentiation was made between asymptomatic and symptomatic bacteriuria in methods or results section. However, no indication or description was provided on the presence of any signs or symptoms of urinary tract infection, thus, the study was included in this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-01 15:22:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thoumsin-1990">
<CHAR_METHODS>
<P>Randomized controlled study. Allocation to treatment not described. Pregnant women nor provider were blinded. Informed consent was taken. No description of sample size or power calculation was provided (the study did not conclude). It was unclear whether the following criteria were met: measurement of contamination of control group, assessment of co-interventions, any deviation from protocol.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-01 15:22:11 +0100" MODIFIED_BY="[Empty name]">
<P>23 women enrolled in the study. Setting: out-patient clinic in Belgium. Inclusion criteria: significant bacteriuria (10,000 CFU/mL or more) without symptoms. Exclusion criteria: not described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-01 15:22:37 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental group: single dose of fosfomycin trometamol 3 g. Control group: 7-day course of nitrofurantoin 100 mg twice a day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-15 02:58:34 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical outcome: medication side effect.<BR/>Laboratory outcomes: rate of no cure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-15 02:58:43 +0100" MODIFIED_BY="[Empty name]">
<P>Type of healthcare provider: not described. Attrition bias: no description of loss to follow-up. from experimental group nor for control group. This study shows preliminary results. No final results were published.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ANC: antenatal care<BR/>CFU: colony forming units<BR/>g: grams<BR/>LTFU: long-term follow-up<BR/>mg: milligrams<BR/>mL: milliliters<BR/>UTI: urinary tract infections</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-10-22 17:33:18 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-10-22 17:29:03 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Adelson-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-22 17:29:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>In this study, 66% of the experimental group were determined to have symptomatic bacteriuria as compared to 33% with asymptomatic bacteriuria. Similarly, in the control group 63% of women were determined to have symptomatic bacteriuria as compared to 37% with asymptomatic bacteriuria. Both symptomatic and asymptomatic bacteriuria were combined when outcomes were assessed; therefore, the study is excluded because of the inability to assess asymptomatic bacteriuria separately. Clarification of data is being sought from authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-15 03:00:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bint-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-15 03:00:33 +0100" MODIFIED_BY="[Empty name]">
<P>In this study 100 pregnant women were screened and randomly allocated in equal numbers to receive either 400 mg pivmecillinam 4 times daily for 7 days or 500 mg ampicillin 4 times daily for 7 days. The treatment did not differ in duration. No distinction was made between asymptomatic and symptomatic bacteriuria. Cure rates were 88% in the pivmecillinam group and 85% in the ampicillin group. Side effects were significantly more frequent in the pivmecillinam group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-26 13:57:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brumfitt-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-26 13:57:59 +0000" MODIFIED_BY="[Empty name]">
<P>This paper includes 2 trials. The first trial compares a 7-day course of treatment with trimethoprim-sulfamethoxazole in 3 different combinations, but of the same duration. In the second trial, 4 drugs were administered at high doses to investigate the possibility that better results might be obtained with high blood levels of antibiotic than smaller dose. There was not a distinction between asymptomatic and symptomatic bacteriuria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-26 13:58:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Campbell_x002d_Brown-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-26 13:58:11 +0000" MODIFIED_BY="[Empty name]">
<P>This is not a randomized controlled trial. In this study bacteriuria was diagnosed from suprapubic aspiration specimens of urine. All participants received the same treatment: single dose of 3 g cephalexin. There was no distinction between symptomatic and asymptomatic pregnant women. The cure rate achieved was 70%. 30% of the participants who were not cured received a 7-day course of antibacterial according to the sensitivity of the organism isolated. 36% continued with the infection and were given continuous antibacterial therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-26 13:58:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davies-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-26 13:58:16 +0000" MODIFIED_BY="[Empty name]">
<P>4 drugs were compared but all were administered during a week. There were 53 women enrolled, 26 (49%) of whom had urinary symptoms at the first clinic attendance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-11 11:16:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Cecco-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-11 11:16:10 +0100" MODIFIED_BY="[Empty name]">
<P>In this study no distinction was made between asymptomatic bacteriuria and symptomatic bacteriuria. The study participants included pregnant women &gt; 8 weeks estimated gestational age who had any bacteriuria &gt; 100,000. The terminology used in the paper to refer to the exposure of interest was 'lower urinary tract infections'. Therefore, this study was excluded. In addition, it was unclear whether randomization was carried out: there was a marked imbalance in the study groups (52 versus 31). If 1 of the 2 antimicrobial treatment regimens failed, women were switched to the other treatment regimen; no description was provided on how many or which women crossed over.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-01 15:05:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harris-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-01 15:05:43 +0100" MODIFIED_BY="[Empty name]">
<P>86 pregnant women were sequentially assigned to 1 of 4 single-dose, single-antimicrobial treatment groups: ampicillin 2 g, plus probenimide 1 g; keflex 2 g, plus probenimide 1 g; macrodantin 200 mg; or, gantrisin 2 g. All participants were diagnosed as having asymptomatic bacteriuria if they had no symptoms of urinary tract infection and had 2 consecutive urine cultures &gt; 100,000 colonies per mL of the same species of micro-organism. The overall no cure rate was 31%, with a recurrence rate of 3.5%.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-26 13:58:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jakobi-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-26 13:58:57 +0000" MODIFIED_BY="[Empty name]">
<P>50 asymptomatic pregnant women were treated with 3 g of amoxicillin or 2 g of cephalexin in accordance with the isolated micro-organism disk sensitivity. The study was not based on randomization. There was no difference in duration of treatment. The immediate cure rate was 84% and the recurrence rate was 12%. The failure of treatment with single-dose treatment was 16%, these participants were treated with the same drug administered for 7 days and were cured. It is possible that these participants had upper UTI or urinary tract malformations.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-26 13:59:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McFadyen-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-26 13:59:28 +0000" MODIFIED_BY="[Empty name]">
<P>The main comparison of interest to the present review, single dose versus 3-day regimen, was not based on randomization. 2 3-day regimens that compared cephalexin 1 g with pivmecillinam-pivampicillin in an independent randomized trial (reported separately) were grouped together in this paper and compared with a non-randomized series of pregnant women who received a single dose of cephalexin 3 g orally.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-26 13:59:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pathak--1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-26 13:59:40 +0000" MODIFIED_BY="[Empty name]">
<P>In this study, participants were randomized to nitrofurantoin or placebo, all of them during a 3-week period.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-29 21:05:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pedler-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-29 21:05:48 +0100" MODIFIED_BY="[Empty name]">
<P>In this study no distinction was made between asymptomatic and symptomatic bacteriuria. Women were randomly allocated to receive either 1 tablet of amoxicillin-clavulanic acid 3 times daily or 250 mg of cephalexin 3 times daily for 7 days. There was no difference in the duration of treatment. The study compared different choices of antimicrobials. Differences in cure rates were not statistically significant. No significant difference in the rate of side effects was found. No toxicity to the fetus was seen which could be ascribed to either drug.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-22 17:33:18 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Rafalsky-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-22 17:33:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>Prospective, multicenter and randomized trial. 58 women were randomized in group 1 (cefixime 400 mg once day, 7 days) and 54 women were included in group 2 (amoxicillin/clavulanate 625mg 3 times a day, 7 days). The treatment did not differ in duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-22 17:32:14 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Robertson-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-22 17:32:14 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women were alternately allocated into treatment with a 2-week course of either cycloserine 250 mg 2 times daily or sulfadimidine 0.5 g 4 times daily. There was no difference in the duration of treatment; what was compared was the difference in choice of antimicrobial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-26 14:00:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanderson-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-26 14:00:05 +0000" MODIFIED_BY="[Empty name]">
<P>This study aimed at reducing reinfection. Participants whose urine was found to be sterile (after 7-day course of pivmecillinam 1 tablet thrice daily), received at random pivmecillinam sachets prophylactically, 100 mg in the evening on alternates days, or were allocated to a control group, who were given no treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-22 10:30:14 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Whalley-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-22 10:30:14 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomized and non-randomized study participants were combined together. This study was excluded because it was not possible to analyze the results of randomized and non-randomized groups separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zinner-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pregnant women with symptomatic and asymptomatic bacteriuria were combined. The majority of women in the study population were described as having symptomatic bacteriuria; therefore, the study is excluded because of the inability to assess asymptomatic bacteriuria separately. An additional concern was the introduction of bias through the sampling method; the sample size of n = 291 was obtained from 25 different study sites in Italy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>
<I>n:</I> number<BR/>UTI: urinary tract infection</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-04-09 16:01:53 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-01-26 14:00:22 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-10-22 17:18:19 +0100" MODIFIED_BY="Heather Maxwell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-10-22 17:18:14 +0100" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-22 10:22:15 +0100" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Anderton-1983">
<DESCRIPTION>
<P>The author used alternate allocation, which is not a good practice.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-14 19:27:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailey-1983">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-28 14:24:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailey-1986">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-09 10:59:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bayrak-2007">
<DESCRIPTION>
<P>A block randomization method was used to ensure an equal number of patients in each group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:07:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brumfitt-1982">
<DESCRIPTION>
<P>Randomization tables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 22:13:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Estebanez-2009">
<DESCRIPTION>
<P>Random number tables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-01 15:01:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gerstner-87_x002d_89">
<DESCRIPTION>
<P>Randomization in groups of 10; 5 patients per regimen.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:09:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lumbiganon-2009">
<DESCRIPTION>
<P>It was generated using computer-generated random numbers with randomly varying blocks of 6-8 (SAS software, SAS Institute, Inc., Cary, NC).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-22 17:18:14 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Masterton-1985">
<DESCRIPTION>
<P>Computer-generated list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-28 14:26:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olsen-1989">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:11:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pregazzi-1987">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-29 20:58:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reeves-1975">
<DESCRIPTION>
<P>Alternated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-28 14:30:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thoumsin-1990">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-10-22 17:18:19 +0100" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-03 09:50:29 +0100" MODIFIED_BY="Sonja L Henderson" RESULT="NO" STUDY_ID="STD-Anderton-1983">
<DESCRIPTION>
<P>Inadequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 14:42:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailey-1983">
<DESCRIPTION>
<P>Unclear. Envelopes, but no mention if they were sealed/opaque.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 14:42:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailey-1986">
<DESCRIPTION>
<P>Unclear.</P>
<P>Envelopes were used but no mention if they were sealed/opaque.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-09 12:42:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bayrak-2007">
<DESCRIPTION>
<P>The blocks were numbered, placed into a bag, and a staff member blinded to the research protocol selected the patients into the treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-03 09:51:20 +0100" MODIFIED_BY="Sonja L Henderson" RESULT="UNKNOWN" STUDY_ID="STD-Brumfitt-1982">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 22:13:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Estebanez-2009">
<DESCRIPTION>
<P>Not mentioned. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 14:36:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gerstner-87_x002d_89">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 22:16:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lumbiganon-2009">
<DESCRIPTION>
<P>The random allocation was concealed by using sealed, opaque treatment boxes numbered sequentially.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-22 17:18:19 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Masterton-1985">
<DESCRIPTION>
<P>Allocation done by secretary. Open-label study. Not mention on how secretary was protected to introduce selection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-01 15:15:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olsen-1989">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-01 15:17:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pregazzi-1987">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-01 15:19:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reeves-1975">
<DESCRIPTION>
<P>Not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-29 21:00:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thoumsin-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-09-25 11:19:53 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-10-03 09:51:53 +0100" MODIFIED_BY="Sonja L Henderson" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-11 11:04:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderton-1983">
<DESCRIPTION>
<P>No loss to follow-up from experimental group 0/33; loss of follow-up for control group 2/34 (6%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-28 14:24:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bailey-1983">
<DESCRIPTION>
<P>2 of the women treated with a 5-day course of cotrimoxazole dropped out of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-28 14:24:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bailey-1986">
<DESCRIPTION>
<P>2 of the women treated with a 5-day course of trimethoprim moved to another city after initial bacteriological follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-09-14 19:29:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bayrak-2007">
<DESCRIPTION>
<P>1 patient in the fosfomycin trometamol group and 5 patients in the cefuroxime axetyl group did not come to the follow-up visit; therefore, they were excluded from the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-28 14:24:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brumfitt-1982">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-01 15:01:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Estebanez-2009">
<DESCRIPTION>
<P>17% LTFU. 22 women excluded from the analyses (10 Amoxiclav, 12 Fosfomycin). Reasons explained in the paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-29 20:47:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gerstner-87_x002d_89">
<DESCRIPTION>
<P>Loss to follow-up from experimental group was 7/53 (13%); loss to follow-up from control group was 10/38 (26%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-09 10:52:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lumbiganon-2009">
<DESCRIPTION>
<P>Delivery outcomes were available in 91.7% and 89.0% of the women in the 1-day and 7-day regimen respectively.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-03 09:51:53 +0100" MODIFIED_BY="Sonja L Henderson" RESULT="YES" STUDY_ID="STD-Masterton-1985">
<DESCRIPTION>
<P>90 out of 102 women enrolled (88.2%) completed the protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-28 14:26:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olsen-1989">
<DESCRIPTION>
<P>2 dropouts in the longer treatment arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-11 11:11:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pregazzi-1987">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-01 15:21:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reeves-1975">
<DESCRIPTION>
<P>5/54 (9%) were lost to follow-up from the experimental arm; 6/46 (13%) from the control one.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-28 14:31:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thoumsin-1990">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-10-15 14:36:39 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:04:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderton-1983">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:05:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailey-1983">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:06:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailey-1986">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:07:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bayrak-2007">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:07:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brumfitt-1982">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:07:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Estebanez-2009">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:08:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gerstner-87_x002d_89">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 14:36:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lumbiganon-2009">
<DESCRIPTION>
<P>No. The protocol was registered in Clinical Trial Registration with N° ISRCTNISrctn.IERCTN11966088.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:10:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Masterton-1985">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:10:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olsen-1989">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:11:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pregazzi-1987">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:13:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reeves-1975">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-11 11:14:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thoumsin-1990">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-10-15 14:35:49 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 11:03:15 +0100" MODIFIED_BY="Nancy  Medley" RESULT="UNKNOWN" STUDY_ID="STD-Anderton-1983">
<DESCRIPTION>
<P>Lack of information in text to assess other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 14:35:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailey-1983">
<DESCRIPTION>
<P>Women in the experimental group were more likely to have a history of urinary tract infection as compared to the control group (50% versus 35%), but we were unclear of the impact of this on specific trial outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 11:04:47 +0100" MODIFIED_BY="Nancy  Medley" RESULT="UNKNOWN" STUDY_ID="STD-Bailey-1986">
<DESCRIPTION>
<P>Lack of information in text to assess other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 10:46:27 +0100" MODIFIED_BY="Nancy  Medley" RESULT="YES" STUDY_ID="STD-Bayrak-2007">
<DESCRIPTION>
<P>Sample size and power calculation provided. No other risk noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 11:05:02 +0100" MODIFIED_BY="Nancy  Medley" RESULT="UNKNOWN" STUDY_ID="STD-Brumfitt-1982">
<DESCRIPTION>
<P>Lack of information in text to assess other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 11:05:13 +0100" MODIFIED_BY="Nancy  Medley" RESULT="UNKNOWN" STUDY_ID="STD-Estebanez-2009">
<DESCRIPTION>
<P>Lack of information in text to assess other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 11:05:31 +0100" MODIFIED_BY="Nancy  Medley" RESULT="UNKNOWN" STUDY_ID="STD-Gerstner-87_x002d_89">
<DESCRIPTION>
<P>Lack of information in text to assess other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 10:46:43 +0100" MODIFIED_BY="Nancy  Medley" RESULT="YES" STUDY_ID="STD-Lumbiganon-2009">
<DESCRIPTION>
<P>Sample size and power calculation provided. No other risk noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 10:46:57 +0100" MODIFIED_BY="Nancy  Medley" RESULT="YES" STUDY_ID="STD-Masterton-1985">
<DESCRIPTION>
<P>Sample size and power calculation provided. No other risk noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 11:05:49 +0100" MODIFIED_BY="Nancy  Medley" RESULT="UNKNOWN" STUDY_ID="STD-Olsen-1989">
<DESCRIPTION>
<P>Lack of information in text to assess other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 11:05:57 +0100" MODIFIED_BY="Nancy  Medley" RESULT="UNKNOWN" STUDY_ID="STD-Pregazzi-1987">
<DESCRIPTION>
<P>Lack of information in text to assess other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 11:06:09 +0100" MODIFIED_BY="Nancy  Medley" RESULT="UNKNOWN" STUDY_ID="STD-Reeves-1975">
<DESCRIPTION>
<P>Lack of information in text to assess other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-04 11:06:19 +0100" MODIFIED_BY="Nancy  Medley" RESULT="UNKNOWN" STUDY_ID="STD-Thoumsin-1990">
<DESCRIPTION>
<P>Lack of information in text to assess other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-10-22 17:17:10 +0100" MODIFIED_BY="Heather Maxwell" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:04:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anderton-1983">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:05:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bailey-1983">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:06:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bailey-1986">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:07:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bayrak-2007">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:07:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brumfitt-1982">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:07:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Estebanez-2009">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:08:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gerstner-87_x002d_89">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-10-22 17:17:10 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Lumbiganon-2009">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:19:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Masterton-1985">
<DESCRIPTION>
<P>Women not blinded to trial treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Olsen-1989">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:11:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pregazzi-1987">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reeves-1975">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-11 11:14:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thoumsin-1990">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-10-03 09:51:36 +0100" MODIFIED_BY="Sonja L Henderson" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:04:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderton-1983">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:05:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailey-1983">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:06:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailey-1986">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:07:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bayrak-2007">
<DESCRIPTION>
<P>The staff members were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:07:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brumfitt-1982">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:07:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Estebanez-2009">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:08:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gerstner-87_x002d_89">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-03 09:51:36 +0100" MODIFIED_BY="Sonja L Henderson" RESULT="YES" STUDY_ID="STD-Lumbiganon-2009">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:10:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Masterton-1985">
<DESCRIPTION>
<P>Personal in charge of outcome assessment blinded to treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olsen-1989">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:11:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pregazzi-1987">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reeves-1975">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-11 11:14:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thoumsin-1990">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-11-02 12:09:44 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-11-02 12:09:44 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-10-25 09:47:22 +0000" MODIFIED_BY="Heather Maxwell">Single-dose antibiotic versus short-course (four- to seven-day) antibiotic for asymptomatic bacteriuria during pregnancy</TITLE>
<TABLE COLS="7" ROWS="29">
<TR>
<TD COLSPAN="7">
<P>
<B>Single dose antibiotic versus short-course (four- to seven-day) antibiotic for asymptomatic bacteriuria during pregnancy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with asymptomatic bacteriuria during pregnancy<BR/>
<B>Settings:</B> high-, low- and middle-income countries<BR/>
<B>Intervention:</B> single-dose antibiotic</P>
<P>
<B>Comparison:</B> short-course (four- to seven-day) <BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Single-dose antibiotic versus short-course (4- to 7-day) antibiotic for asymptomatic bacteriuria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>No cure - all trials</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.28 </B>
<BR/>(0.87 to 1.88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1502<BR/>(13 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>166 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>212 per 1000</B>
<BR/>(144 to 312)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>138 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>177 per 1000</B>
<BR/>(120 to 259)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Recurrent asymptomatic bacteriuria - all trials</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.13 </B>
<BR/>(0.77 to 1.66)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>445<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>169 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>191 per 1000</B>
<BR/>(130 to 281)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>139 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>157 per 1000</B>
<BR/>(107 to 231)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Pyelonephritis - Same antimicrobial agent only<SUP>4</SUP>
</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 3.09 </B>
<BR/>(0.54 to 17.55)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>102<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>21 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>64 per 1000</B>
<BR/>(11 to 366)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>87 per 1000</B>
<BR/>(15 to 491)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Low birthweight - Same antimicrobial agent only</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.65 </B>
<BR/>(1.06 to 2.57)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>714<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>80 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>132 per 1000</B>
<BR/>(85 to 206)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Preterm delivery - Same antimicrobial agent only</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.17 </B>
<BR/>(0.77 to 1.78)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>804<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>91 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>99 per 1000</B>
<BR/>(47 to 206)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>89 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>97 per 1000</B>
<BR/>(46 to 201)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Side effects - all trials</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.70 </B>
<BR/>(0.56 to 0.88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1460<BR/>(12 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>194 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>136 per 1000</B>
<BR/>(109 to 171)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>182 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>127 per 1000</B>
<BR/>(102 to 160)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded twice due to serious risk of bias concerns. Most of the pooled effect provided by studies &#8220;B&#8221; or &#8220;C&#8221; (as specified by WHO criteria)<B>*</B> with a substantial proportion (i.e. &gt; 40%) from studies &#8220;C&#8221; (-2).<BR/>
<SUP>2</SUP> Downgraded once for imprecision. Wide confidence interval crossing the line of no effect (-1).<BR/>
<SUP>3</SUP> Downgraded once for imprecision. Small sample size and few events (-1).</P>
<P>
<SUP>4</SUP> All data available for this outcome came from trials testing the same microbial agents.</P>
<P>
<B>* </B>"A" studies are of low risk of bias; "B" studies (-1) are those with serious design limitations, including lack of allocation concealment, blinding (where relevant) or other problems with the conduct of the study; and "C" studies (-2) have the same problems as B studies but to a greater degree. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-11-02 12:03:06 +0000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2015-10-25 09:50:42 +0000" MODIFIED_BY="Heather Maxwell">Single-dose antibiotic versus short-course (four- to seven-day) antibiotic for asymptomatic bacteriuria during pregnancy (subgrouped by trial quality)</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Single-dose antibiotic versus short-course (four- to seven-day) antibiotic for asymptomatic bacteriuria during pregnancy (subgrouped by trial quality) </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with asymptomatic bacteriuria during pregnancy<BR/>
<B>Settings:</B> high- middle- and low-income countries<BR/>
<B>Intervention:</B> single-dose antibiotic </P>
<P>
<B>Comparison:</B> short-course (4-7 day) antibiotic <BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Single-dose antibiotic versus short-course (4- to 7-day) antibiotic for asymptomatic bacteriuria (subgrouped by trial quality)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Same antimicrobial agent - No cure (good quality studies)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.72 </B>
<BR/>(1.27 to 2.33)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>803<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>137 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>236 per 1000</B>
<BR/>(175 to 320)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>134 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>230 per 1000</B>
<BR/>(170 to 312)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Different antimicrobial agents - No cure (good quality studies)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.36 </B>
<BR/>(0.24 to 7.75)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>84<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>68 per 1000</B>
<BR/>(12 to 388)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded once for imprecision. Wide confidence interval crossing the line of no effect (-1).<BR/>
<SUP>2</SUP> Downgraded once for imprecision. Small sample size and few events (-1).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-11-02 12:18:21 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-11-02 12:18:21 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Single dose versus short-course (4-7 day) antibiotic for asymptomatic bacteriuria</NAME>
<DICH_OUTCOME CHI2="26.998352385347275" CI_END="1.8795221230948558" CI_START="0.8670529791656519" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.276575597540994" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="121" I2="55.552843267159076" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.2740474419846398" LOG_CI_START="-0.06195436520390147" LOG_EFFECT_SIZE="0.10604653839036918" METHOD="MH" MODIFIED="2015-09-24 11:52:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0077314291370734756" P_Q="0.4578068295077109" P_Z="0.21602020444709935" Q="0.5512516220618833" RANDOM="YES" SCALE="4.264516010511736" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.22698569344272762" TOTALS="YES" TOTAL_1="772" TOTAL_2="730" WEIGHT="99.99999999999999" Z="1.2371802263172833">
<NAME>No cure</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Short course (4-7 day)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 4-7 day treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="25.831395356529256" CI_END="2.1247717132262363" CI_START="0.8474252599435613" DF="9" EFFECT_SIZE="1.3418588679147554" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="107" I2="65.15867658026022" ID="CMP-001.01.01" LOG_CI_END="0.32731227602775365" LOG_CI_START="-0.07189859474782091" LOG_EFFECT_SIZE="0.12770684063996632" MODIFIED="2015-07-01 15:57:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.002176841935051188" P_Z="0.20985005633603504" STUDIES="10" TAU2="0.29886110614453804" TOTAL_1="662" TOTAL_2="624" WEIGHT="83.70961027566493" Z="1.253977917722799">
<NAME>Same antimicrobial agent</NAME>
<DICH_DATA CI_END="13.291657910857118" CI_START="1.2778232378484726" EFFECT_SIZE="4.121212121212121" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.1235791552564698" LOG_CI_START="0.10647078172819013" LOG_EFFECT_SIZE="0.61502496849233" ORDER="2" O_E="0.0" SE="0.5974544933781601" STUDY_ID="STD-Anderton-1983" TOTAL_1="33" TOTAL_2="34" VAR="0.356951871657754" WEIGHT="6.671016516818286"/>
<DICH_DATA CI_END="121.70743925248131" CI_START="0.3668361974345442" EFFECT_SIZE="6.681818181818182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.085317124882156" LOG_CI_START="-0.43552781703021654" LOG_EFFECT_SIZE="0.8248946539259698" ORDER="3" O_E="0.0" SE="1.4807567972630389" STUDY_ID="STD-Bailey-1983" TOTAL_1="21" TOTAL_2="20" VAR="2.1926406926406927" WEIGHT="1.6099415860154471"/>
<DICH_DATA CI_END="1.816767939244651" CI_START="0.1376070078074701" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2592994572244536" LOG_CI_START="-0.861359448552416" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="4" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Bailey-1986" TOTAL_1="30" TOTAL_2="30" VAR="0.43333333333333335" WEIGHT="5.899356195436516"/>
<DICH_DATA CI_END="2.203569073312686" CI_START="0.4856460325405999" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.3431266685007499" LOG_CI_START="-0.31368015485933715" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="1" O_E="0.0" SE="0.38581157928792614" STUDY_ID="STD-Brumfitt-1982" TOTAL_1="29" TOTAL_2="24" VAR="0.1488505747126437" WEIGHT="10.364771768023138"/>
<DICH_DATA CI_END="1.142438815932367" CI_START="0.31341889797301337" EFFECT_SIZE="0.5983827493261455" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.05783295043599846" LOG_CI_START="-0.5038748207648129" LOG_EFFECT_SIZE="-0.22302093516440724" ORDER="5" O_E="0.0" SE="0.32994992530166734" STUDY_ID="STD-Gerstner-87_x002d_89" TOTAL_1="53" TOTAL_2="37" VAR="0.10886695320657586" WEIGHT="11.59870907804277"/>
<DICH_DATA CI_END="2.404073689961094" CI_START="1.2884053514236196" EFFECT_SIZE="1.7599492627239575" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="51" LOG_CI_END="0.38094777558236065" LOG_CI_START="0.11005252000431452" LOG_EFFECT_SIZE="0.24550014779333762" MODIFIED="2009-10-30 14:10:47 +0000" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.159125214079686" STUDY_ID="STD-Lumbiganon-2009" TOTAL_1="371" TOTAL_2="370" VAR="0.0253208337559059" WEIGHT="15.439383137754449"/>
<DICH_DATA CI_END="4.270067353351766" CI_START="0.3258004830960371" EFFECT_SIZE="1.1794871794871795" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6304347253665492" LOG_CI_START="-0.48704827605639955" LOG_EFFECT_SIZE="0.07169322465507488" MODIFIED="2015-07-01 15:57:44 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.6564150466659102" STUDY_ID="STD-Masterton-1985" TOTAL_1="39" TOTAL_2="23" VAR="0.43088071348940915" WEIGHT="5.921349837183294"/>
<DICH_DATA CI_END="7.9651785724420225" CI_START="0.9842842729383221" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.901195516754457" LOG_CI_START="-0.006879454070018646" LOG_EFFECT_SIZE="0.4471580313422192" ORDER="6" O_E="0.0" SE="0.5334077329058977" STUDY_ID="STD-Olsen-1989" TOTAL_1="15" TOTAL_2="24" VAR="0.2845238095238095" WEIGHT="7.615610499871411"/>
<DICH_DATA CI_END="10.494858328367584" CI_START="1.0587194951529546" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0209765803530566" LOG_CI_START="0.024780910207618474" LOG_EFFECT_SIZE="0.5228787452803376" MODIFIED="2011-03-03 08:20:40 +0000" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.5851702678915278" STUDY_ID="STD-Pregazzi-1987" TOTAL_1="22" TOTAL_2="22" VAR="0.3424242424242424" WEIGHT="6.841217365912024"/>
<DICH_DATA CI_END="1.2309434608757417" CI_START="0.3464732349515797" EFFECT_SIZE="0.6530612244897959" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.09023810557665804" LOG_CI_START="-0.4603303089938735" LOG_EFFECT_SIZE="-0.18504610170860772" MODIFIED="2011-03-03 08:20:52 +0000" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.3234066120763363" STUDY_ID="STD-Reeves-1975" TOTAL_1="49" TOTAL_2="40" VAR="0.10459183673469388" WEIGHT="11.748254290607608"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3894140860393319" CI_END="1.953663081095141" CI_START="0.49191583914198783" DF="2" EFFECT_SIZE="0.9803253612641253" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.2908496695989857" LOG_CI_START="-0.30810919341705306" LOG_EFFECT_SIZE="-0.008629761909033648" MODIFIED="2011-06-13 07:44:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8230758125882085" P_Z="0.9549609592781751" STUDIES="3" TAU2="0.0" TOTAL_1="110" TOTAL_2="106" WEIGHT="16.29038972433506" Z="0.0564780774816204">
<NAME>Different antimicrobial agents</NAME>
<DICH_DATA CI_END="7.747402764426775" CI_START="0.24001645309697386" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.889156134232018" LOG_CI_START="-0.6197589864371057" LOG_EFFECT_SIZE="0.13469857389745618" MODIFIED="2009-10-30 14:14:24 +0000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.8863442111313531" STUDY_ID="STD-Bayrak-2007" TOTAL_1="44" TOTAL_2="40" VAR="0.7856060606060605" WEIGHT="3.8470164565336544"/>
<DICH_DATA CI_END="1.9179212638525929" CI_START="0.38966660633577055" EFFECT_SIZE="0.8644939965694682" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.28283077417133395" LOG_CI_START="-0.40930681079831155" LOG_EFFECT_SIZE="-0.06323801831348881" MODIFIED="2011-06-13 07:44:28 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.40656504354747136" STUDY_ID="STD-Estebanez-2009" TOTAL_1="53" TOTAL_2="56" VAR="0.16529513463475728" WEIGHT="9.93027663540702"/>
<DICH_DATA CI_END="14.661618230962407" CI_START="0.16143265143318902" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1661819068666315" LOG_CI_START="-0.7920086201523426" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="4" O_E="0.0" SE="1.1502508087703842" STUDY_ID="STD-Thoumsin-1990" TOTAL_1="13" TOTAL_2="10" VAR="1.323076923076923" WEIGHT="2.513096632394387"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.672996886656816" CI_END="1.6591368857709983" CI_START="0.7746171173566749" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1336647792694547" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.21988221862384402" LOG_CI_START="-0.1109129102786596" LOG_EFFECT_SIZE="0.05448465417259222" METHOD="MH" MODIFIED="2015-07-01 15:27:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9135170499284414" P_Q="0.861044105695268" P_Z="0.5185098810610045" Q="0.030640844092743" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="213" WEIGHT="99.99999999999999" Z="0.645644089395734">
<NAME>Recurrent asymptomatic bacteriuria</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Short course (4-7 day)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 4-7 day treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.5798991398493554" CI_END="1.656754158282259" CI_START="0.7603519935308247" DF="5" EFFECT_SIZE="1.1223708509402759" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="34" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.2192580692989116" LOG_CI_START="-0.11898531106332284" LOG_EFFECT_SIZE="0.05013637911779435" MODIFIED="2011-03-03 08:23:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.764416985729223" P_Z="0.5612173613914804" STUDIES="6" TAU2="0.0" TOTAL_1="166" TOTAL_2="147" WEIGHT="94.15606274811036" Z="0.5810342675790888">
<NAME>Same antimicrobial agent</NAME>
<DICH_DATA CI_END="11.1657331835418" CI_START="0.6171224841873102" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.0478872457336508" LOG_CI_START="-0.20962863024969952" LOG_EFFECT_SIZE="0.4191293077419757" ORDER="2" O_E="0.0" SE="0.7386710503565985" STUDY_ID="STD-Bailey-1983" TOTAL_1="24" TOTAL_2="18" VAR="0.5456349206349206" WEIGHT="6.3519404684532015"/>
<DICH_DATA CI_END="3.51077932597227" CI_START="0.410165341167152" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.54540353224961" LOG_CI_START="-0.38704104015436036" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="3" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Bailey-1986" TOTAL_1="30" TOTAL_2="30" VAR="0.30000000000000004" WEIGHT="13.894869774741379"/>
<DICH_DATA CI_END="12.544542152665894" CI_START="0.054597363659053225" EFFECT_SIZE="0.8275862068965517" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0984548151763904" LOG_CI_START="-1.2628283275510905" LOG_EFFECT_SIZE="-0.08218675618735007" ORDER="1" O_E="0.0" SE="1.3870294065781892" STUDY_ID="STD-Brumfitt-1982" TOTAL_1="29" TOTAL_2="24" VAR="1.9238505747126435" WEIGHT="3.041141309188679"/>
<DICH_DATA CI_END="1.6285806430448146" CI_START="0.36456201442065883" EFFECT_SIZE="0.7705314009661836" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.21180926855777446" LOG_CI_START="-0.4382285846852101" LOG_EFFECT_SIZE="-0.11320965806371783" ORDER="4" O_E="0.0" SE="0.3818354527341977" STUDY_ID="STD-Gerstner-87_x002d_89" TOTAL_1="46" TOTAL_2="29" VAR="0.14579831296472973" WEIGHT="30.67987246262896"/>
<DICH_DATA CI_END="2.0384083797144354" CI_START="0.5085802360277116" EFFECT_SIZE="1.018181818181818" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.30929119600467697" LOG_CI_START="-0.29364052098076393" LOG_EFFECT_SIZE="0.007825337511956526" ORDER="5" O_E="0.0" SE="0.35416507511738143" STUDY_ID="STD-Olsen-1989" TOTAL_1="15" TOTAL_2="24" VAR="0.12543290043290042" WEIGHT="23.514395003408488"/>
<DICH_DATA CI_END="3.2086911883830402" CI_START="0.5540507557144057" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5063279216343763" LOG_CI_START="-0.2564504484177765" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-03-03 08:23:41 +0000" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.4480597903824619" STUDY_ID="STD-Pregazzi-1987" TOTAL_1="22" TOTAL_2="22" VAR="0.2007575757575757" WEIGHT="16.673843729689654"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.042990041502726034" CI_END="7.463642542677792" CI_START="0.23190842919197807" DF="1" EFFECT_SIZE="1.3156297420333838" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.8729508315074682" LOG_CI_START="-0.6346834657430676" LOG_EFFECT_SIZE="0.11913368288220039" MODIFIED="2011-06-13 07:45:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8357441480155788" P_Z="0.7567481858933099" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="5.843937251889633" Z="0.30975380199370267">
<NAME>Different antimicrobial agents</NAME>
<DICH_DATA CI_END="16.46605204218904" CI_START="0.06780080200726994" EFFECT_SIZE="1.0566037735849056" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2165894836978635" LOG_CI_START="-1.1687651688870409" LOG_EFFECT_SIZE="0.023912157405411364" MODIFIED="2011-06-13 07:45:05 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="1.4011691306243352" STUDY_ID="STD-Estebanez-2009" TOTAL_1="53" TOTAL_2="56" VAR="1.9632749326145553" WEIGHT="2.702488433252452"/>
<DICH_DATA CI_END="14.661618230962407" CI_START="0.16143265143318902" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1661819068666315" LOG_CI_START="-0.7920086201523426" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="2" O_E="0.0" SE="1.1502508087703842" STUDY_ID="STD-Thoumsin-1990" TOTAL_1="13" TOTAL_2="10" VAR="1.323076923076923" WEIGHT="3.141448818637181"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18049293187704513" CI_END="17.553749528558566" CI_START="0.542864107272599" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0869565217391304" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.2443698971913046" LOG_CI_START="-0.26530887178833984" LOG_EFFECT_SIZE="0.4895305127014824" METHOD="MH" MODIFIED="2015-07-01 15:28:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6709499702912569" P_Q="1.0" P_Z="0.20369977701097342" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="48" WEIGHT="100.0" Z="1.2710812312433994">
<NAME>Pyelonephritis</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Short course (4-7 day)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 4-7 day treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.18049293187704513" CI_END="17.553749528558566" CI_START="0.542864107272599" DF="1" EFFECT_SIZE="3.0869565217391304" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.2443698971913046" LOG_CI_START="-0.26530887178833984" LOG_EFFECT_SIZE="0.4895305127014824" MODIFIED="2011-04-27 16:02:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6709499702912569" P_Z="0.20369977701097342" STUDIES="2" TAU2="0.0" TOTAL_1="54" TOTAL_2="48" WEIGHT="100.0" Z="1.2710812312433994">
<NAME>Same antimicrobial agent</NAME>
<DICH_DATA CI_END="19.88625198277208" CI_START="0.2545728578912588" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.298552938147906" LOG_CI_START="-0.5941879019251811" LOG_EFFECT_SIZE="0.3521825181113625" ORDER="50263" O_E="0.0" SE="1.1118053386771944" STUDY_ID="STD-Bailey-1983" TOTAL_1="24" TOTAL_2="18" VAR="1.236111111111111" WEIGHT="69.56521739130434"/>
<DICH_DATA CI_END="99.95416281504153" CI_START="0.25011464551267176" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="50264" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Bailey-1986" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="30.434782608695652"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.605965811718674" CI_END="1.781841749017322" CI_START="0.7746197722743391" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1748403507935485" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="36" I2="23.253022314940896" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.25086913035158737" LOG_CI_START="-0.11091142178313103" LOG_EFFECT_SIZE="0.06997885428422819" METHOD="MH" MODIFIED="2015-11-02 12:18:01 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.27172020779879036" P_Q="1.0" P_Z="0.44831463415540296" Q="0.0" RANDOM="NO" SCALE="2.997385280336177" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="409" TOTAL_2="395" WEIGHT="100.00000000000001" Z="0.7582277890127721">
<NAME>Preterm delivery</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Short course (4-7 day)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 4-7 day treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.605965811718674" CI_END="1.781841749017322" CI_START="0.7746197722743391" DF="2" EFFECT_SIZE="1.1748403507935485" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="36" I2="23.253022314940896" ID="CMP-001.04.01" LOG_CI_END="0.25086913035158737" LOG_CI_START="-0.11091142178313103" LOG_EFFECT_SIZE="0.06997885428422819" MODIFIED="2011-04-27 16:02:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.27172020779879036" P_Z="0.44831463415540296" STUDIES="3" TAU2="0.0" TOTAL_1="409" TOTAL_2="395" WEIGHT="100.00000000000001" Z="0.7582277890127721">
<NAME>Same antimicrobial agent</NAME>
<DICH_DATA CI_END="1.8270763539566743" CI_START="0.07696722673656511" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.2617566970017776" LOG_CI_START="-1.1136941615463398" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="50261" O_E="0.0" SE="0.8079466429027216" STUDY_ID="STD-Bailey-1983" TOTAL_1="24" TOTAL_2="18" VAR="0.6527777777777778" WEIGHT="12.407942869376052"/>
<DICH_DATA CI_END="24.57080823388317" CI_START="0.29882418384741555" EFFECT_SIZE="2.7096774193548385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.390419442428082" LOG_CI_START="-0.5245842579728641" LOG_EFFECT_SIZE="0.43291759222760895" ORDER="50262" O_E="0.0" SE="1.1248826530367149" STUDY_ID="STD-Bailey-1986" TOTAL_1="31" TOTAL_2="28" VAR="1.2653609831029184" WEIGHT="2.8522495790832667"/>
<DICH_DATA CI_END="1.9409680853822056" CI_START="0.7925592914916567" EFFECT_SIZE="1.240295243302351" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="31" LOG_CI_END="0.2880183945041022" LOG_CI_START="-0.10096823825286498" LOG_EFFECT_SIZE="0.09352507812561862" MODIFIED="2009-10-30 13:30:58 +0000" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.228492673596329" STUDY_ID="STD-Lumbiganon-2009" TOTAL_1="354" TOTAL_2="349" VAR="0.05220890188719854" WEIGHT="84.7398075515407"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.565495217532159" CI_START="1.0590794081609067" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6483516483516483" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.4091712094021113" LOG_CI_START="0.024928524067063817" LOG_EFFECT_SIZE="0.21704986673458762" METHOD="MH" MODIFIED="2015-11-02 12:18:21 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.02680971142005396" Q="0.0" RANDOM="NO" SCALE="7.355580857818146" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="364" TOTAL_2="350" WEIGHT="100.0" Z="2.2142772673893116">
<NAME>Low birthweight</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Short course (4-7 day)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 4-7 day treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.565495217532159" CI_START="1.0590794081609067" DF="0" EFFECT_SIZE="1.6483516483516483" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="28" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.4091712094021113" LOG_CI_START="0.024928524067063817" LOG_EFFECT_SIZE="0.21704986673458762" MODIFIED="2015-05-30 00:54:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02680971142005396" STUDIES="1" TAU2="0.0" TOTAL_1="364" TOTAL_2="350" WEIGHT="100.0" Z="2.2142772673893116">
<NAME>Same antimicrobial agent</NAME>
<DICH_DATA CI_END="2.565495217532159" CI_START="1.0590794081609067" EFFECT_SIZE="1.6483516483516483" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="28" LOG_CI_END="0.4091712094021113" LOG_CI_START="0.024928524067063817" LOG_EFFECT_SIZE="0.21704986673458762" MODIFIED="2015-05-30 00:54:54 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.2257060553977749" STUDY_ID="STD-Lumbiganon-2009" TOTAL_1="364" TOTAL_2="350" VAR="0.05094322344322344" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.929274689206864" CI_END="0.881202078893568" CI_START="0.5551335847895408" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.699417521213318" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="140" I2="8.50261994169259" I2_Q="81.53488507579276" ID="CMP-001.06" LOG_CI_END="-0.05492448695143331" LOG_CI_START="-0.2556024976770425" LOG_EFFECT_SIZE="-0.15526349231423792" METHOD="MH" MODIFIED="2015-09-25 11:31:48 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3630547551654132" P_Q="0.019957470693676926" P_Z="0.00242274381834939" Q="5.4156175258299" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="738" TOTAL_2="722" WEIGHT="100.0" Z="3.0328270840386966">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Short course (4-7 day)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 4-7 day treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.365383926682553" CI_END="0.9720740379715269" CI_START="0.6054731073849262" DF="7" EFFECT_SIZE="0.7671796975799302" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="125" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-0.012300655796009698" LOG_CI_START="-0.21790514165998776" LOG_EFFECT_SIZE="-0.11510289872799873" MODIFIED="2015-09-25 11:31:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6154668525375981" P_Z="0.028200871348067397" STUDIES="9" TAU2="0.0" TOTAL_1="628" TOTAL_2="616" WEIGHT="88.9274395498282" Z="2.1944806804681045">
<NAME>Same antimicrobial agent</NAME>
<DICH_DATA CI_END="15.799330419622734" CI_START="0.06718793177039936" EFFECT_SIZE="1.0303030303030303" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1986386818136034" LOG_CI_START="-1.172708727484868" LOG_EFFECT_SIZE="0.012964977164367635" ORDER="2" O_E="0.0" SE="1.3929412065809121" STUDY_ID="STD-Anderton-1983" TOTAL_1="33" TOTAL_2="34" VAR="1.9402852049910875" WEIGHT="0.6995227375957784"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Bailey-1983" TOTAL_1="24" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="4" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Bailey-1986" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.3550607834766451"/>
<DICH_DATA CI_END="2.5065328167371788" CI_START="0.15370062002202212" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.3990733949792232" LOG_CI_START="-0.8133243805705233" LOG_EFFECT_SIZE="-0.20712549279565" ORDER="1" O_E="0.0" SE="0.7121684548237004" STUDY_ID="STD-Brumfitt-1982" TOTAL_1="29" TOTAL_2="24" VAR="0.507183908045977" WEIGHT="3.108456670437044"/>
<DICH_DATA CI_END="1.3627308391703088" CI_START="0.05722181214873223" EFFECT_SIZE="0.2792452830188679" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.1344100842964281" LOG_CI_START="-1.2424383927080915" LOG_EFFECT_SIZE="-0.5540141542058317" ORDER="5" O_E="0.0" SE="0.8087676109023352" STUDY_ID="STD-Gerstner-87_x002d_89" TOTAL_1="53" TOTAL_2="37" VAR="0.6541050484446711" WEIGHT="4.1818270053915985"/>
<DICH_DATA CI_END="1.122364361698981" CI_START="0.6521726220297537" EFFECT_SIZE="0.8555555555555555" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="90" LOG_CI_END="0.05013386813861936" LOG_CI_START="-0.18563743667230542" LOG_EFFECT_SIZE="-0.06775178426684303" MODIFIED="2009-10-30 14:01:16 +0000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.13849323153271853" STUDY_ID="STD-Lumbiganon-2009" TOTAL_1="375" TOTAL_2="385" VAR="0.01918037518037518" WEIGHT="63.07000759124617"/>
<DICH_DATA CI_END="2.7277201623185725" CI_START="0.23462817368186242" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.4357998138602988" LOG_CI_START="-0.6296198398764117" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="6" O_E="0.0" SE="0.6258327785172862" STUDY_ID="STD-Olsen-1989" TOTAL_1="15" TOTAL_2="24" VAR="0.39166666666666666" WEIGHT="3.2774841551690312"/>
<DICH_DATA CI_END="2.040485547143221" CI_START="0.21781308133580674" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3097335229915851" LOG_CI_START="-0.6619160411029475" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-03-03 08:17:41 +0000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.5707517636920413" STUDY_ID="STD-Pregazzi-1987" TOTAL_1="22" TOTAL_2="22" VAR="0.3257575757575757" WEIGHT="4.2607294017197415"/>
<DICH_DATA CI_END="0.9381521656019636" CI_START="0.1644624582770919" EFFECT_SIZE="0.39279869067103107" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="-0.027726714582976906" LOG_CI_START="-0.7839332224789196" LOG_EFFECT_SIZE="-0.4058299685309482" MODIFIED="2015-09-25 11:31:48 +0100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.4441994460206617" STUDY_ID="STD-Reeves-1975" TOTAL_1="47" TOTAL_2="40" VAR="0.19731314784506274" WEIGHT="9.97435120479219"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0135707668114302" CI_END="0.5838244187065453" CI_START="0.04125563390908665" DF="2" EFFECT_SIZE="0.15519679921101" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="-0.23371774441527524" LOG_CI_START="-1.384516735391553" LOG_EFFECT_SIZE="-0.8091172399034141" MODIFIED="2011-06-13 07:43:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.602429116745367" P_Z="0.0058500674096878405" STUDIES="3" TAU2="0.0" TOTAL_1="110" TOTAL_2="106" WEIGHT="11.07256045017181" Z="2.7560688911202504">
<NAME>Different antimicrobial agents</NAME>
<DICH_DATA CI_END="4.8235043133041575" CI_START="0.042834328908561196" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6833626712179824" LOG_CI_START="-1.368208032862395" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2009-10-30 14:18:28 +0000" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="1.2051027870155837" STUDY_ID="STD-Bayrak-2007" TOTAL_1="44" TOTAL_2="40" VAR="1.4522727272727274" WEIGHT="1.4878737593307034"/>
<DICH_DATA CI_END="0.7185840668016852" CI_START="0.01283989171551811" EFFECT_SIZE="0.09605488850771869" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.14352241665658785" LOG_CI_START="-1.8914386388490394" LOG_EFFECT_SIZE="-1.0174805277528136" MODIFIED="2011-06-13 07:43:54 +0100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="1.0267346412406888" STUDY_ID="STD-Estebanez-2009" TOTAL_1="53" TOTAL_2="56" VAR="1.0541840235236462" WEIGHT="7.596346303371893"/>
<DICH_DATA CI_END="2.9484348479116433" CI_START="0.00837524952213576" EFFECT_SIZE="0.15714285714285714" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.46959153553757393" LOG_CI_START="-2.0770022452496373" LOG_EFFECT_SIZE="-0.8037053548560318" ORDER="3" O_E="0.0" SE="1.4958817926769272" STUDY_ID="STD-Thoumsin-1990" TOTAL_1="13" TOTAL_2="10" VAR="2.2376623376623375" WEIGHT="1.9883403874692125"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-11-02 11:54:13 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Single dose versus short-course (4-7 day) antibiotic for asymptomatic bacteriuria (subgrouped by trial quality)</NAME>
<DICH_OUTCOME CHI2="25.831395356529264" CI_END="2.1395467060817857" CI_START="1.2450975197553606" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6321593969778756" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="107" I2="65.15867658026023" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.33032177152674674" LOG_CI_START="0.09520336800445187" LOG_EFFECT_SIZE="0.2127625697655993" METHOD="MH" MODIFIED="2015-09-24 15:12:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00217684193505141" P_Q="0.44477843900079794" P_Z="3.893366595090186E-4" Q="0.5839240909280339" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2988611061445381" TOTALS="SUB" TOTAL_1="662" TOTAL_2="624" WEIGHT="200.00000000000003" Z="3.5472082810329475">
<NAME>Same antimicrobial agent</NAME>
<GROUP_LABEL_1>single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>short course (4-7 day)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 4-7day course</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.35110544252785736" CI_END="2.3307102661819434" CI_START="1.2712125809338857" DF="1" EFFECT_SIZE="1.7212867898413244" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="54" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.3674882891279912" LOG_CI_START="0.10421818234526904" LOG_EFFECT_SIZE="0.2358532357366301" MODIFIED="2015-07-01 16:00:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5534882412013242" P_Z="4.452371842815039E-4" STUDIES="2" TAU2="0.0" TOTAL_1="410" TOTAL_2="393" WEIGHT="100.00000000000001" Z="3.5117078298793594">
<NAME>No cure (good quality studies)</NAME>
<DICH_DATA CI_END="4.270067353351766" CI_START="0.3258004830960371" EFFECT_SIZE="1.1794871794871795" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6304347253665492" LOG_CI_START="-0.48704827605639955" LOG_EFFECT_SIZE="0.07169322465507488" MODIFIED="2015-07-01 16:00:03 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.6564150466659102" STUDY_ID="STD-Masterton-1985" TOTAL_1="39" TOTAL_2="23" VAR="0.43088071348940915" WEIGHT="5.550361218369571"/>
<DICH_DATA CI_END="2.404073689961094" CI_START="1.2884053514236196" EFFECT_SIZE="1.7599492627239575" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="51" LOG_CI_END="0.38094777558236065" LOG_CI_START="0.11005252000431452" LOG_EFFECT_SIZE="0.24550014779333762" MODIFIED="2015-05-29 23:09:10 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.159125214079686" STUDY_ID="STD-Lumbiganon-2009" TOTAL_1="371" TOTAL_2="370" VAR="0.0253208337559059" WEIGHT="94.44963878163044"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.838985117183423" CI_END="2.415871673479597" CI_START="0.725262155543932" DF="7" EFFECT_SIZE="1.3236843647279888" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="53" I2="66.40911272484217" ID="CMP-002.01.02" LOG_CI_END="0.3830738616627356" LOG_CI_START="-0.13950498359883887" LOG_EFFECT_SIZE="0.12178443903194841" MODIFIED="2015-05-29 23:18:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.004015924373997337" P_Z="0.3609691281767552" STUDIES="8" TAU2="0.4514627068489256" TOTAL_1="252" TOTAL_2="231" WEIGHT="100.00000000000001" Z="0.9135200038974256">
<NAME>No cure (poor quality studies)</NAME>
<DICH_DATA CI_END="2.203569073312686" CI_START="0.4856460325405999" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.3431266685007499" LOG_CI_START="-0.31368015485933715" LOG_EFFECT_SIZE="0.014723256820706378" MODIFIED="2015-05-29 23:16:46 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.38581157928792614" STUDY_ID="STD-Brumfitt-1982" TOTAL_1="29" TOTAL_2="24" VAR="0.1488505747126437" WEIGHT="15.696430514979838"/>
<DICH_DATA CI_END="1.2309434608757417" CI_START="0.3464732349515797" EFFECT_SIZE="0.6530612244897959" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.09023810557665804" LOG_CI_START="-0.4603303089938735" LOG_EFFECT_SIZE="-0.18504610170860772" MODIFIED="2015-05-29 23:18:23 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.3234066120763363" STUDY_ID="STD-Reeves-1975" TOTAL_1="49" TOTAL_2="40" VAR="0.10459183673469388" WEIGHT="16.945775949466192"/>
<DICH_DATA CI_END="13.291657910857118" CI_START="1.2778232378484726" EFFECT_SIZE="4.121212121212121" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.1235791552564698" LOG_CI_START="0.10647078172819013" LOG_EFFECT_SIZE="0.61502496849233" MODIFIED="2015-05-29 23:16:02 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.5974544933781601" STUDY_ID="STD-Anderton-1983" TOTAL_1="33" TOTAL_2="34" VAR="0.356951871657754" WEIGHT="11.655870591369897"/>
<DICH_DATA CI_END="121.70743925248131" CI_START="0.3668361974345442" EFFECT_SIZE="6.681818181818182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.085317124882156" LOG_CI_START="-0.43552781703021654" LOG_EFFECT_SIZE="0.8248946539259698" MODIFIED="2015-05-29 23:16:02 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="1.4807567972630389" STUDY_ID="STD-Bailey-1983" TOTAL_1="21" TOTAL_2="20" VAR="2.1926406926406927" WEIGHT="3.5636941100977912"/>
<DICH_DATA CI_END="1.816767939244651" CI_START="0.1376070078074701" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2592994572244536" LOG_CI_START="-0.861359448552416" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-05-29 23:16:02 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Bailey-1986" TOTAL_1="30" TOTAL_2="30" VAR="0.43333333333333335" WEIGHT="10.649658546516216"/>
<DICH_DATA CI_END="10.494858328367584" CI_START="1.0587194951529546" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0209765803530566" LOG_CI_START="0.024780910207618474" LOG_EFFECT_SIZE="0.5228787452803376" MODIFIED="2015-05-29 23:17:54 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.5851702678915278" STUDY_ID="STD-Pregazzi-1987" TOTAL_1="22" TOTAL_2="22" VAR="0.3424242424242424" WEIGHT="11.869165653721337"/>
<DICH_DATA CI_END="1.142438815932367" CI_START="0.31341889797301337" EFFECT_SIZE="0.5983827493261455" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.05783295043599846" LOG_CI_START="-0.5038748207648129" LOG_EFFECT_SIZE="-0.22302093516440724" MODIFIED="2015-05-29 23:17:16 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.32994992530166734" STUDY_ID="STD-Gerstner-87_x002d_89" TOTAL_1="53" TOTAL_2="37" VAR="0.10886695320657586" WEIGHT="16.81648569222154"/>
<DICH_DATA CI_END="7.9651785724420225" CI_START="0.9842842729383221" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.901195516754457" LOG_CI_START="-0.006879454070018646" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2015-05-29 23:17:16 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.5334077329058977" STUDY_ID="STD-Olsen-1989" TOTAL_1="15" TOTAL_2="24" VAR="0.2845238095238095" WEIGHT="12.802918941627189"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3894140860393319" CI_END="1.9757402452694275" CI_START="0.5004162109376118" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9943301500682129" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.29572984639457583" LOG_CI_START="-0.30066862982051457" LOG_EFFECT_SIZE="-0.0024693917129693407" METHOD="MH" MODIFIED="2015-11-02 11:54:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8230758125882085" P_Q="0.6907966950958153" P_Z="0.9870505136512995" Q="0.1582244641976315" RANDOM="NO" SCALE="19.083052547259584" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="110" TOTAL_2="106" WEIGHT="200.0" Z="0.016230486878025047">
<NAME>Different antimicrobial agents</NAME>
<GROUP_LABEL_1>single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>short course (4-7 day)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 4-7 day treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.747402764426775" CI_START="0.24001645309697386" DF="0" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.889156134232018" LOG_CI_START="-0.6197589864371057" LOG_EFFECT_SIZE="0.13469857389745618" MODIFIED="2015-05-29 23:49:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.72639419743841" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="40" WEIGHT="100.0" Z="0.34992604950615014">
<NAME>No cure (good quality studies)</NAME>
<DICH_DATA CI_END="7.747402764426775" CI_START="0.24001645309697386" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.889156134232018" LOG_CI_START="-0.6197589864371057" LOG_EFFECT_SIZE="0.13469857389745618" MODIFIED="2015-05-29 23:49:30 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.8863442111313531" STUDY_ID="STD-Bayrak-2007" TOTAL_1="44" TOTAL_2="40" VAR="0.7856060606060605" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2236366477465919" CI_END="1.963581251200998" CI_START="0.43943754505394245" DF="1" EFFECT_SIZE="0.9289086739511669" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.2930488766877513" LOG_CI_START="-0.3571028401939255" LOG_EFFECT_SIZE="-0.03202698175308708" MODIFIED="2015-05-29 23:50:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6362828553537703" P_Z="0.846881658556548" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="100.00000000000001" Z="0.19309871569868112">
<NAME>No cure (poor quality studies)</NAME>
<DICH_DATA CI_END="1.9179212638525929" CI_START="0.38966660633577055" EFFECT_SIZE="0.8644939965694682" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.28283077417133395" LOG_CI_START="-0.40930681079831155" LOG_EFFECT_SIZE="-0.06323801831348881" MODIFIED="2015-05-29 23:50:48 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.40656504354747136" STUDY_ID="STD-Estebanez-2009" TOTAL_1="53" TOTAL_2="56" VAR="0.16529513463475728" WEIGHT="90.44246593821666"/>
<DICH_DATA CI_END="14.661618230962407" CI_START="0.16143265143318902" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1661819068666315" LOG_CI_START="-0.7920086201523426" LOG_EFFECT_SIZE="0.18708664335714445" MODIFIED="2015-05-29 23:50:48 +0100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="1.1502508087703842" STUDY_ID="STD-Thoumsin-1990" TOTAL_1="13" TOTAL_2="10" VAR="1.323076923076923" WEIGHT="9.557534061783354"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-05-29 23:00:45 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Single dose versus long-course (14 day) antibiotic for asymptomatic bacteriuria</NAME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-05-29 23:00:40 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Single dose versus continuous (treatment continued until delivery) antibiotic for asymptomatic bacteriuria</NAME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-10-22 17:18:20 +0100" MODIFIED_BY="Heather Maxwell">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-10-22 17:18:20 +0100" MODIFIED_BY="Heather Maxwell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-10-22 17:18:20 +0100" MODIFIED_BY="Heather Maxwell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVAAAALbCAIAAAAjFU8IAAAlc0lEQVR42u3dv64cxfr18S0hIQIH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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-09-24 11:52:29 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Single dose versus short-course (4-7 day) antibiotic for asymptomatic bacteriuria, outcome: 1.6 No cure.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-09-11 11:52:08 +0100" MODIFIED_BY="[Empty name]"/>
<EXTENSIONS/>
</COCHRANE_REVIEW>